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Abstract
The Disease Gene Association Problem (DGAP) is a bioinformatics problem in which
genes are ranked with respect to how involved they are in the presentation of a partic-
ular disease. Previous approaches have shown the strength of both Monte Carlo and
evolutionary computation (EC) based techniques. Typically these past approaches
improve ranking measures, develop new gene relation denitions, or implement more
complex EC systems.
This thesis presents a hybrid approach which implements a multi-objective genetic
algorithm, where input consists of centrality measures based on various relational bi-
ological evidence types merged into a complex network. In an eort to explore the
eectiveness of the technique compared to past work, multiple objective settings and
dierent EC parameters are studied including the development of a new exchange
methodology, safe dealer-based (SDB) crossover. Successful results with respect to
breast cancer and Parkinson's disease compared to previous EC techniques and pop-
ular known databases are shown. In addition, the newly developed methodology is
also successfully applied to Alzheimers, further demonstrating the exibility of the
technique.
Across all three cases studies the strongest results were produced by the shortest
path-based measures stress and betweenness in a single objective parameter setting.
When used in conjunction in a multi-objective environment, competitive results were
also obtained but fell short of the single objective settings studied as part of this
work. Lastly, while SDB crossover fell short of expectations on breast cancer and
Parkinson's, it achieved the best results when applied to Alzheimers, illustrating the
potential of the technique for future study.
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Chapter 1
Introduction
Understanding the link between genes and how they pertain to the presentation of
various diseases is important in extending the life expectancy of humans. This prob-
lem is primarily referred to as the Disease Gene Association Problem. Information
gathered as part of this problem is often used in two ways. Firstly, it is used for gene
prioritization, the ranking of known problematic genes based on their contribution
to the presentation of a disease in hopes of cementing known disease causing genes.
Secondly, it is used to identify new genes for future study that have yet to be inves-
tigated in relation to a given disease, in the hopes of gaining further insight into how
the disease functions. This second use is based on the principle of guilt by association,
which states that genes that are found to be highly interacting with already known
contributors are also likely to be \guilty". For example, in the case of breast cancer,
it is known that BRCA1 is one of the strongest contributors to the presentation of the
disease. Genes that are found to be frequently interacting with BRCA1 (through, for
example, protein-protein interaction networks) should thus be considered for future
study in relation to breast cancer.
A signicant challenge of the Disease Gene Association Problem is that the mod-
elling of relationships between genes can often contain hundreds of thousands of inter-
actions. As such, presenting this data in a manner suitable for study often becomes
a problem for computer scientists to tackle.
Recently, there have been eorts to tackle the Disease Gene Association Problem
using articial intelligence techniques from the eld of computer science. In addition
to this style of approach, biologists often take the route of developing new ways
to relate genes together, rening previous relations, or applying techniques to new
diseases. As such, it stands to reason that a methodology that combines the recent
advances of both of these styles of approaches is a strong candidate for improving on
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current techniques.
The goal of this thesis is to improve upon past techniques and their application
to breast cancer and Parkinson's disease. Additionally, the methodology developed
in this thesis will be applied to Alzheimer's disease in order to broaden the number
of diseases studied.
1.1 Thesis Structure
The remainder of this thesis is structured as follows. Chapter 2 introduces necessary
computer science background, including formal denitions for graph theory, approx-
imation algorithms and evolutionary computation. Chapter 3 outlines the biological
principles that make up the Disease Gene Association Problem, as well as dening
several biological evidence types relating genes together. This chapter also describes
three dierent approaches to scoring the eectiveness of a disease gene association
problem methodology. Chapter 4 reviews three families of literature related to this
topic. Chapter 5 denes the specic details of the methodology presented in this
work as well as data generation procedures. Additionally, as part of this work, three
case studies are investigated. Chapter 6 contains the methodology applied to breast
cancer, Chapter 7 explores Parkinson's disease, while Chapter 8 contains the case
study of Alzheimer's disease. Lastly, Chapter 9 concludes this thesis and provides
avenues for future work.
2
Chapter 2
Computer Science Background
Bioinformatics and specically the Disease Gene Association Problem (DGAP) re-
quires a broad knowledge of fundamental computer science concepts. This is due to
the complexity required to model the relationships in the input data of the DGAP. As
such, this chapter will introduce the fundamentals of graph theory and algorithms to
build a knowledge base sucient for modeling and studying the DGAP as interaction
between genes.
2.1 Graph Theory: A Formal Denition
A graph G is typically dened as G = (V;E), where V is a set of vertices (also known
as nodes) and E is a set of pairs of vertices implying some sort of relationship between
the two nodes. This relationship in terms of graphs is often called an edge. Edges
come with two implicit properties, weight and direction. The weight of an edge is a
numerical value representing the cost to traverse that edge. For example, consider
cities as nodes connected by highways as edges. Toll-free highways would possess a
weight of zero, while toll based highways would have a weight matching their cost.
A graph with weights for each edge is called weighted, while a graph without weights
is called unweighted ; in this case, all edges have the same cost or weight. Continuing
with the example of cities connected by highways, directed edges can be thought of as
one-way streets while undirected edges are two way streets. Graphs are directed if all
edges are directed otherwise they are undirected. Mathematically this is represented
by the notion of a particular relation between nodes being symmetric or not. Figure
2.1 contains an example of a directed and weighted graph, while Figure 2.2 contains
an example of an undirected and unweighted graph.
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Figure 2.1: An Example of a directed and weighted graph.
2.1.1 Topological Features of Graphs
In addition to the properties dened in the previous section, graphs also include
several dierent topological properties. This section will list and dene several other
fundamental graph properties and further topological features.
 The degree of a node is the number of connections a node possesses. In directed
graphs, this is often separated into in-degree and out-degree.
 The neighbour of a node V is any other node that is directly connected to V
via an edge. For the purpose of this thesis, N(V ) will be dened as the set of
nodes neighbouring V .
 A traversal (also known as a path) is an ordered list of nodes that implies visiting
each node in the list via edge connections acorrding to the order specied by
the list.
 The shortest path is dened as a traversal through the graph between any two
given nodes such that the path cost is minimal. For the purpose of this thesis,
the shortest path between two nodes will be dened as dist(u; v). For example,
4
Figure 2.2: An Example of an undirected and unweighted graph with an example
clique.
in Figure 2.1, dist(A;D) is equal to ve. This is achieved through the traversal
A;B;C;D.
 The diameter of a graph is dened as the maximal shortest path. In the case
of Figure 2.2, this is represented by dist(A; J) = 6 and the traversal J, I, E, F,
D, A.
 A graph cut is a particular partition of the nodes in a graph that separates
vertices into two disjoint subsets. A cut can be made in Figure 2.2 between the
nodes D and F to separate the graph into the subsets of vertices fA, B, C, Dg
and fE, F, G, H, I, Jg.
 Graphs that are complete possess edges between every pair of nodes.
 A clique is a subset of nodes in a graph which, with respect to the group, form
a complete graph as shown in Figure 2.2 with the bounded box.
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Figure 2.3: Visual comparison of a random network versus a scale-free network. Image
taken from [11].
2.1.2 Network Types
Building on the notion of topological features, there exist families of graphs often also
called networks. Belonging to these families requires adhering to several additional
denitions and constraints [7]. The trade-o, however, is that several additional
assumptions and properties about the network become true. Often, modeling real
world data tends towards falling into these families. For examples, road networks in
cities, maps of the Internet, social interaction networks, epidemic modeling and other
biologically inspired graphs all fall into the category of complex networks [9][27]. The
following sections outline three network types studied in current literature, namely,
random graphs, scale-free networks, and complex networks. Figure 2.3 contains a
visual example of a random network versus a scale-free network.
Random Graphs
Random graphs are often used as benchmarking tools for testing new approaches
to solving graph problems. They are created by generating a list of n nodes, and
iteratively adding edges following a particular sampling distribution with respect to
n. The goal of this approach is to iterate until certain graph properties such as
community structures become true or are discovered [8].
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Complex Networks
A complex network is most commonly dened as a network in which there are non-
trivial topological features. However, this denition is not entirely strong. Addition-
ally, this denition does not exclude the appearance of some of the features introduced
in Section 2.1.1. It does however imply that they are perhaps dicult both visually
and computationally to discover. This behaviour often presents itself most heavily
when the data used to generate a graph is real-world inspired [47].
Complex networks dier from random graphs in the sense that they are not nec-
essarily governed by a probability function, and cannot be inspected at any point
during the creation process. As such, it can be dicult to extract information and
meaning from them. Diculty aside, complex networks still tend to have inherent
properties. The most notable of these properties is that complex networks tend to
form small highly interconnected areas known as communities [60].
Scale-Free Networks
An extension to the notion of complex networks is that of scale-free networks. Scale-
free networks inherit all of the implicit properties of a complex network but also add
a new constraint. Namely, that the connectivity of each node in a scale-free network
follows a power law based distribution. This implies that there is no function that
neatly maps to the sorted distribution of degree of nodes in the graph. Formally, the
probability distribution of the number of edges originating from a node k is dened
as P (k)  k , where  is taken to be a constant 2 <  < 3 [54].
2.1.3 Centrality Measures
As stated in the previous section, it is dicult to extract meaning from complex
networks. Due to this, researchers studying complex networks have introduced and
dened the notion of centrality measures. Centrality measures provide a measure
indicating how important or central a node is in a graph. These measures allow
for meaning to be extracted from extremely large networks and aord the ability of
ranking of nodes by relative importance. Measures vary not only in computation,
but also in their approach. For example, one measure may reward a node with a
higher score for being isolated, while another favours nodes with higher degree. These
measures may of course be adapted and combined, as what provides an eective means
of measuring centrality in one graph problem, may not generalize to others.
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An additional important consideration when working with centrality measures ap-
plied to large networks is that of pre-computation. If the network is to stay static
throughout the duration of an experiment, computation time can often be exponen-
tially reduced by pre-computing network statistics and centrality measures. This is
especially true for the more computationally complex measures. A further optimiza-
tion could include not loading the graph as a data structure at all, and instead simply
loading attributes of node centrality. In the case of representing a graph as a matrix,
this can reduce the memory requirements signicantly.
The following subsections will provide denitions of centrality measures and the
properties used to compute them based on [62]. However, Section 2.1.12 and the
denition of bridging is instead based on [34]. Note that this is a small sample of
measures and the notion of centrality continues to be improved in the eld of complex
network analysis ([5], [67]).
2.1.4 Degree
As dened previously, degree is the number of nodes in direct connection to a given
node n. This can be broken down into two forms. In-degree is the number of incoming
connections to node n, while out-degree is the number of outgoing connection from
node n. The sum of these two numbers is the total degree.
A high degree can imply that a node is highly connected in a network, thus
inferring that it is central and important. Conversely, a node with low degree can be
thought of as less important and a node on the fringes of a network.
2.1.5 Eigenvector
Eigenvector is a recursive measure of the reachability of a node in a graph. A Node n
with a high eigenvector will have many neighbours. These neighbours will also have
many connections, thus contributing to the overall score of n. If n were to have a
low eigenvector, its local neighbourhood would be sparsely connected with few overall
nodes. Therefore, if a node has a high eigenvector relative to the rest of the network,
it can be thought of as a central node.
The following recursive equation is used to compute eigenvector for a given node,
where  is an eigenvalue of the graph represented as an adjacency matrix, and N(v)
is the set of neighbours of v. Initially, all nodes are given a default eigenvector value
of one.
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Eig(v) =
1

X
wN(v)
Eig(w) (2.1)
2.1.6 Closeness
The closeness of a node n is computed by nding the shortest path from n to all other
nodes in the graph. By taking the summation of these distances and computing the
reciprocal, a measure for connectivity relative to the whole network is dened.
It follows simply that nodes with high closeness are central to a graph as it takes
them less time to reach all other nodes in the graph on average. Conversely nodes
that must travel further would be taken to be less central under this measure.
2.1.7 Eccentricity
Eccentricity is much like closeness, as it takes a given node n and computes shortest
paths from n to all other nodes in the graph. Next, instead of summation, the
maximum distance path is found, and the reciprocal value of this distance is the
eccentricity value.
Eccentricity can be a dicult measure to work with. Consider the case of an
extremely central node that has one node far from it. The resulting eccentricity value
would then be overall very low. To combat these problems eccentricity should only
be used when the topology of the graph can be guaranteed to be fairly regular and
without trails of nodes branching o from the main body of the graph.
2.1.8 Radiality
Radiality is a centrality measure computed respective to the diameter (G) of a
graph. As such it is dened as follows:
Cr(v) =
P
wN(v)(G + 1  dist(v; w))
n  1 (2.2)
Subtracting shortest paths from the longest shortest path, this centrality measure
will return a high value if the node is involved in shortest path traversals.
2.1.9 Centroid Value
The centroid value of a node in a network is much like eigenvector, that is, the measure
is highly inuenced by neighbours that are more than one edge away. This increases
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the complexity drastically. Centroid value is dened as follows:
Cc(v) = minff(v; w) : wN(v)g (2.3)
where
f(v; w) = v(w)  w(v) (2.4)
and v(w) refers to the number of nodes in the graph that are closer in distance to v
than w.
Note that similar to eccentricity, centroid value must be compared to the overall
average to obtain a meaningful interpretation. A node with a comparatively high
centroid value relative to the network can be interpreted as a central node.
2.1.10 Stress
The stress of a given node n in a graph is computed by referencing all shortest paths
in the network and counting how many of these paths contain the node n.
Stress diers from the previous measures as it does not necessarily reward a higher
value based on connectivity relative to the graph. It instead rewards higher score
based on how \travelled" the edges are. In a complex network based on commu-
nication, stress can reward nodes that connect highly dense areas such as cliques.
Note that comparison to the average stress value of the network as a benchmark can
provide a more accurate comparison between nodes.
2.1.11 Betweenness
Betweenness functions much like stress, but scales the number of shortest paths that
pass through a given node n. The motivation is that stress does not account for
the situation of a node being redundant. Betweenness attempts to combat this by
dividing the total number of shortest paths that use n by all other shortest paths of
equal length. Thus if betweenness returns a high value, not only is the node providing
an important connection, but it is a critical non-redundant connection.
2.1.12 Bridging
This centrality measure also functions like stress as it rewards nodes that occur in
shortest paths rather than direct connectivity. However, it diers vastly in computa-
tion. Simply put, it combines betweenness and eigenvector to create a new value that
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rewards critical connections and places a lower emphasis on degree. This relies on
the notion that nodes with a high degree typically exist in cliques, and bridging as a
measure rewards nodes that \bridge" gaps between highly connected areas. By min-
imizing this measure, it is possible to nd the opposite. That is, minimizing bridging
searches for nodes that are part of highly connected areas that are non-bridging.
2.1.13 Limitations of Centrality Measures
Though centrality measures provide an eective way paired with pre-computation to
analyze complex networks, they are not without aws. In the previous section, eccen-
tricity, centroid value, and stress all required reference to the overall average values
of the network to be eective as raw comparison between two numerical values. With
this in mind, recall that not every centrality measure or combination of measures will
work for all graph types. When searching for important nodes in a telecommunication
network, bridging may be useful. This may not be the case for a biologically generated
network. These two types of networks often dier in both size and connectivity [27].
Individual measures are also being iterated on and new functions are being created
all the time. Choosing correct measures for complex network analysis is eventually
reduced to empirical study.
Additionally, issues when ranking with centrality measures can occur when there
are many nodes with a low score. This is due to centrality measures only being func-
tions which allow for a simple numeric comparison between nodes. These functions
are often not normalized or scaled. This problem is illustrated by the question of if
a node v in a network has the highest bridging value, and a node w has the second
most bridging, how much less \bridging" is it in comparison? What would that mean?
This problem becomes exacerbated at low scores [9]. The meaning is easy to discover
when working with something as simple as degree for example, but when looking at
centroid value it is not so clear.
On a nal note, most if not all centrality measures are related. That is not to say
that these measures are ineective, instead it is the case that most centrality rankings
are based on neighbours and as such are highly inuenced by a node's degree. All the
measures discussed in this report except for stress and betweenness take into account
neighbours in some way. However, stress as a measure is not without its own problems
as outlined in the denition of betweenness.
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2.1.14 Community Detection
Often, real world data tends to have several highly connected nodes (hubs) while
the remaining system is sparsely interconnected in comparison [69]. In terms of the
cities and roads in North America as an example, hubs could be capital cities or
suburbs and sparse regions could be inhospitable areas. While nding large cities on
an unfamiliar map may seem trivial and unimportant, consider telecommunication
networks. In these systems hubs may be areas of the network under signicant stress
and in need of infrastructure upgrades and failsafe mechanisms.
However, if these hubs are so important, how does automatic detection work? The
process of nding and detecting these hubs is known as community detection. This is
an ongoing eld of research which seeks to make the process both more ecient and
accurate [69]. This can be a challenging problem as networks vary in size, topology,
and connectivity. Specically, the problem of community detection can be shown
to be NP-complete [69]. A proof sketch of this can be found in Fortunato's work
in [22] where community detection is reduced to that of a search for a maximally
\weak-clique" based on the notion that a search for a maximal standard clique is
already known to be NP-complete [38]. Currently popular methodologies in the eld
are discussed in Section 4.3 of this thesis.
2.2 Algorithms
The study of algorithms is a fundamental part of computer science. Optimality of
these algorithms is then of course a further focus. However, it is known that there
exists problems that for large enough inputs, can take lifetimes to solve optimally,
specically, the set of problems that are known as NP-Complete [23]. To combat
this, there is a class of methodologies known as approximation algorithms. These
algorithms attempt to create solutions that are nearly optimal, but do not necessarily
result in solutions that are actually optimal. Approximation algorithms come in many
forms, but this section will focus on articial intelligence (AI) techniques, specically
those inspired by biological principles.
2.2.1 Random Search
While not biologically inspired, random search is a fundamental theoretical starting
point for understanding approximation algorithms. Implementation is done by ran-
domly generating numerous candidate solutions and keeping track of the best found.
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Note that this does not attempt to use regression, learn, or exploit any portion of the
solution landscape. Thus this technique is most often used to measure the minimal
results necessary to be achieved by an approach to be accepted as useful. However,
this benchmarking tool begins to fall apart when as part of a problem denition, a
relative ranking between candidates must be produced, i.e. to determine how much
better one item is in comparison to another.
2.2.2 Principles of Evolutionary Computation
Evolutionary computation (EC) is a subeld of AI in which populations of candidate
solutions are permuted subject to selection inspired by biological principles such as
Darwinian evolution [32]. The eectiveness of these candidate solutions is typically
measured by a heuristic often referred to as a tness function (see Section 2.2.8).
This diers from the typical denition of biological tness which is dened by how
much a given individual inuences the next generation. Instead, tness as a heuristic
represents how successful a candidate is at solving its respective problem. As such,
the motivation of Darwinian evolution in the context of EC is to exploit the structure
of successful candidates and distribute benecial traits throughout the population
until genetic diversity becomes stale. This nal state is referred to as convergence.
Early techniques in this eld include work by Fogel [21] and Schwefel [6], who
developed evolutionary programming and evolutionary strategies respectively. EC
quickly expanded to include further techniques such as, particle swarm optimization
[39], ant colony optimization [17], self-organizing maps [40], and more. In general, EC
techniques possess several common properties and are listed below in no particular
order.
 Population of candidates
 Biologically inspired exchange or reproduction property
 Fitness or heuristic measure of success
 Convergence criteria: success level or maximum iterations reached
2.2.3 Genetic Algorithms
In addition to the early techniques listed in the previous section, Holland popularized
a technique he named the genetic algorithm (GA) [32]. GAs have been shown to be
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C1 1 0 1 0 0 1 0 1 1 0
C2 1 1 1 1 1 1 1 1 1 1
Table 2.1: Examples individuals for the Max Ones problem of size ten. C1 is a random
candidate solution, while C2 is the optimal solution.
able to solve numerous challenging problems and remain an active area of study in
the eld.
The structure of a standard GA and associated denitions are listed below, while
further specication can be found in the coming sections.
1. Initialization: Generate an initial population of candidate solutions. Typically
taken to be random unless specied otherwise.
2. Fitness: Score each individual in the population in accordance with the tness
function.
3. Stopping criteria: Determine if the best solution, a sucient solution, or other
stopping criterion has been met. Otherwise, continue.
4. Selection: Randomly select pairs of individuals to undergo crossover and mu-
tation operations.
5. New Population: Repeat step 4 until an entirely new population of individuals
has been made of the same size.
6. Continue: Go to step 2.
2.2.4 Individuals
Individuals in a GA are candidate solutions to the problem denition. These candi-
dates have an internal data structure representation known as a chromosome. The
set of individuals being evolved in a GA are known as the population. The size of
this set, and the amount of evolutionary epochs (iterations of the algorithm) are both
parameters of the GA methodology. Table 2.1 contains two example individuals of
chromosomes for the Max Ones problem of size ten. The Max Ones problem at-
tempts to take a binary string (of a given variable size) containing zeros and ones and
generate an individual containing only ones.
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C1 1 0 1 0 0 1 0 1 1 0
C2 0 1 0 1 0 1 1 1 1 1
Table 2.2: Example of initial state of one-point crossover applied to the Max Ones
problem. See Table 2.3 for nished state. Emphasized entry is dened as the start
position of the exchange.
C1' 1 0 1 1 0 1 1 1 1 1
C2' 0 1 0 0 0 1 0 1 1 0
Table 2.3: Example result of one-point crossover applied to the Max Ones problem.
Emphasized entries represent new genetic material obtained as result of crossover.
2.2.5 Selection
Selection is the process by which the GA rewards strong individuals for possessing
successful \genetic material". A standard approach to this segment of a GA is that
of tournament selection. This begins by randomly selecting k individuals from the
population. Next, the strongest of this subset is selected, as measured by which
individual has the strongest tness value. This individual can be said to have won the
\tournament", and often proceeds to exchange information with another tournament
winner. Typically k is kept quite small, i.e. three or four. This is due to the fact
that increasing k greatly increases the selection pressure in the population but can
quickly lower the diversity of genetic material. As such, as k grows too large, a GA's
results may fall into a local optimum instead of a global optimum.
2.2.6 Crossover
Crossover refers to the process that allows individuals to distribute genetic material
throughout the population via an exchange process. These new individuals, called
children, make up the next generation of candidate solutions. Since crossover is
an operator that is highly representation dependent, studies often dene their own
custom crossover operators. Further, the rate at which individuals in the population
undergo crossover is subject to choice via parameter at run time. Tables 2.2 and
2.3 contain an example of one-point crossover on the previously dened Max Ones
problem. One-point crossover in the case of the Max Ones problem is accomplished by
taking two individuals, selecting a random index, and swapping all genetic material
between the two chromosomes after that point.
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C1 1 0 1 0 0 1 0 1 1 0
C1' 1 0 1 0 1 1 0 1 1 0
Table 2.4: Example of single-bit mutation applied to the Max Ones problem. C1 is
the original chromosome, while C1' is the result of a benecial mutation.
2.2.7 Mutation
Mutation is an operator which attempts to duplicate the micro-level changes that
happen upon creation of new individuals between generations. As such, the rate of
mutation is a parameter to be dened at run time. Table 2.4 contains a worked
example of single-bit mutation applied again to the Max Ones problem. Single-bit
mutation in this case is dened as taking a single random index in the chromosome,
and ipping the bit at that position.
2.2.8 Fitness Functions and Principles
As stated previously, tness in relation to EC diers from biological tness. This
new notion of tness only refers to how adept a chromosome is at solving a particular
problem. Just as there exist numerous schemes for encoding problems into chromo-
some structures, there exists just as many tness function choices. The choice of
tness function is often left to what is best able to describe the tness landscape.
A tness landscape can be thought of as the possible solution space spanned by all
chromosomes and their resulting tness. Figure 2.4 contains a visual representation
of a tness landscape where the EC technique is trying to nd global minima. The
tness for this particular problem would be distance of a given coordinate to the
known minimum and thus minimizing that distance. This diers signicantly from
the notion of the Max Ones tness function as in that case it is simply the summation
of the chromosome being maximized.
Something these examples have in common is that they are optimizing a single
value. This family of tness functions is called single objective. It should come as no
surprise that there exists another family of functions called multi-objective. Consider
the example of a factory producing some product. Inside of the factory they would
like to both maximize prot as well as worker safety. How should the success of an
individual then be measured? An entry level technique is that of weighted sum. This
in eect compresses the multi-objective problem back down to a single objective i.e.P1
i=1wioi where i is the id of each objective, oi is the raw value of an objective, and
wi is a weight value. The diculty of this approach is that for every problem or
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Figure 2.4: An Example of a tness landscape: The Holder Table function [36]
parameter setting, new weight values must be examined empirically.
A second more advanced technique adapted from economic principles, is the idea
of maintaining Pareto fronts. The motivation behind Pareto approaches is to keep
a set of distinct solutions which for each item in the set, are \non-dominated" [16].
An individual x is said to be strictly dominated by an individual y for the following
equation:
x  y $ 8i(xi  yi) ^ 9i(xi < yi) (2.5)
where xi and yi are various objectives of an optimization problem. As illustrated
by Figure 2.5, Pareto fronts often contain multiple solutions. These solutions are
then examined for exceptional individuals and can be passed to other researchers as
candidate solutions for their own potential work.
Adaptation into a tness technique can be done naively based on Algorithm 1. In
this scheme, Pareto rank becomes the new tness value for the purposes of selection
operators. While an innovative solution, Pareto front management introduces large
amounts of comparisons into tness evaluations, increasing execution time. Diversity
of a population also decreases as the number of objectives increases. This is due
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Figure 2.5: An Example of a Pareto front taken from [72]
to the quality of solutions in middle tier fronts uctuating wildly. More advanced
implementations that attempt to preserve diversity of solutions and reduce execution
time are NSGA-II [16] and SPEA2 [76].
Algorithm 1 Naive Pareto Fitness Function
1: procedure Pareto(Pop) . Returns a rank for each individual
2: Rank  1
3: while unranked individuals exist do
4: for each unranked pi 2 Pop do
5: if no pj(j 6= i) dominates pi then
6: rank(pi) Rank
7: Rank  Rank + 1
A third technique for multi-objective problems without the disadvantages of Pareto
front management is Sum of Ranks, presented in Section 5.1.6 for use in this thesis.
2.2.9 Genetic Programming
Genetic Programming (GP) is an EC technique developed by Koza [41] which also
exploits the principles of Darwinian evolution and natural selection. It diers from
a GA in that the internal representation of individuals are typically tree-based and
as such have adapted crossover and mutation operators associated with standard
methods. These tree-based individuals can be thought of as functions or programs,
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making GP suited for evolving solutions to problems with which a typical GA would
struggle.
To illustrate these dierences, consider the Articial Ant problem [42]. In this
problem, an environment containing a path with rewards is dened. Standard GAs
at most could be expected to recover the path through evolution, whereas GP has
been shown to be able to evolve a program which traverses areas systemically looking
for rewards [42].
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Chapter 3
Biological Background
As the Disease Gene Association Problem (DGAP) is a biologically inspired problem,
the purpose of this chapter is to introduce the fundamental denitions required to
understand the basics of genetics and how small changes in genetic information can
lead to the presentation of malicious diseases. This chapter also gives a formal de-
nition to the DGAP, its input data structure, and methods of measuring success of a
methodology.
3.1 Genetics and DNA
Genetics is based upon the study of deoxyribonucleic acid (DNA). Of particular in-
terest is how small changes in the overall structure of DNA can lead to such drastic
changes in the health of cells and organisms [19]. DNA is made up of two long strings
called nucleotides, which bond with each other and form a double helix. These four
nucleotides are known as guanine, cytosine, adenine, and thymine, typically denoted
by G, C, A, and T respectively. Bonds formed in the double helix model are formed
between the pairs G,C and A,T due to the chemical structure of each nucleotide and
its potential for hydrogen bonding. Figure 3.1 contains a visualization of the double
helix model where the bridges between strands are the bonds between G, C, A, and
T nucleotides.
3.2 Genes
The long strands of nucleotides inside of DNA can be thought of as a list of approx-
imately three billion characters. However, some portions of this list are considered
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Figure 3.1: DNA Double Helix visualization taken from [37]
more important than others. Subsets of the DNA sequence that are actually respon-
sible for distinct behaviours are known as genes and are typically inheritable [13].
Every cell in a human, for example, contains two complete sets of genes, each set
found lying on one of the two strands of DNA. If one gene on one strand is some-
how deactivated, damaged, or incapable of functioning, the other set of genes can
potentially take over [28].
Despite this, what is it that makes these genes actually able to do anything? How
do they represent functionality much less physical attributes? Essentially a gene can
be thought of as a blueprint or algorithm for developing proteins (see Section 3.3)
to accomplish various tasks. This process is dened as gene expression. Consider
the case of something akin to the generation of a human nerve cell, muscle cell, or
bone cell. Of the entirety of information contained in human DNA, these cells are
\expressing" very little of the potential information at their disposal.
3.3 Proteins
Proteins in the context of DNA and genetics dier from the more typically known
protein nutrient, in that a protein is a complex molecule which accomplishes low level
tasks for cells as dictated by its respective gene. These tasks may include: provid-
ing cell structure, assisting in DNA replication, transport of lower level structures
(atoms), communication between other proteins, and more.
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3.4 Phenotypes and Disease Presentation
A phenotype is dened as the total set of visible and observable characteristics or traits
of some organism. These individual traits result from at least one and sometimes
many more genes being expressed. Some examples of phenotypes include blood type,
hair colour, and for birds, nesting habits. This leads to the denition of a high level
phenotype and a low level phenotype. Examples of high level phenotypes are hair
colour, eye colour, and various behaviours. However, low level phenotypes can be
properties of a cell. For example, these might include type or shape. In summary,
phenotypes result from genes being expressed, which is an interaction of proteins.
Of particular interest to biologists is when genes are expressed and manifest into
some sort of genetic disorder via a single nucleotide polymorphism (SNP). An SNP is
when a single G, C, A, or T is permuted and replaced by another nucleotide. These
changes can sometimes be far reaching and quite harmful, for example in the case of
Parkinsons disease and the SNCA gene [64]. However, not all undesirable phenotypes
are necessarily bad. An example of a possibly undesirable phenotype that is not
particularly harmful is that of male pattern baldness.
3.5 Bioinformatics
Bioinformatics is a hybrid eld of study which typically combines biologically inspired
problems with large scale computer science algorithmic approaches. Contributions
to the eld of bioinformatics typically focus on the methodology surrounding the
processing of large amounts of biological data. For example, shotgun sequencing of
DNA takes short stands of DNA, and using substring matching (tiling), attempts
to construct larger strings. This process is recursively repeated until a chosen length
sequence is found. As an approach, shotgun sequencing was a fundamental part of the
initial study of human genome data generation [35]. The following section introduces
an additional bioinformatics problem that is the focus of this thesis.
3.6 The Disease Gene Association Problem
The Disease Gene Association Problem (DGAP) is a bioinformatics problem in which
search strategies inspired by computer science are used to nd and rank various genes
based on their involvement in the presentation of a given disease. Results from the
DGAP typically are of the form of either a ranking of each gene, representing how
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likely they are to be involved in disease presentation, or a reduced subset of genes
which are considered to be highly involved. The motivation for this result format is
to be able to pass this ranked list or highly involved subset to a biologist for focused
study on specic genes. Use of this list would help to provide an ordering by priority,
so that the deadliest genes are studied most rapidly.
Typically, known information about the disease being studied is included in the
computational approach and is used in hope of increasing the accuracy of methodolo-
gies. The following two subsections are extended assumptions to the DGAP problem
and serve as known principles that can optimize DGAP search strategies.
3.6.1 Modularity Principle
The Modularity principle states that there does not exist a one-to-one relationship
between genes and genetic diseases [55]. Take for example the real world gene BRCA1.
This gene is frequently present in cases of breast cancer. However, with this gene
highly interacting on the protein level with other genes is not enough to guarantee a
presentation of breast cancer [2]. As such, the DGAP and its respective methodologies
need to be able to return more than a single individual gene as deadly.
3.6.2 Guilt-by-Association Principle
Consider the other genes interacting with BRCA1 in the previous example. If it
is found that the interaction between this group of genes and BRCA1 is common,
they are considered to be \guilty by association", i.e. likely to also contribute to
the presentation of the disease. Genes involved in the same disease tend to closely
interact [26]. Strong search strategies should take advantage of this and examine
frequent gene interactions.
3.7 DGAP Input Data
Unsurprisingly, the inputs to the DGAP are various gene interaction measures. How-
ever, even a small subset of interactions contains a large amount of relations between
numerous genes. Representing all of these relations at once in a graph easily forms a
complex network [2] (see Section 2.1.2). Interaction measures that can be used in the
DGAP are explored in the following subsections. Note that all of these form complex
networks.
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3.7.1 Protein-Protein Interaction
Perhaps one of the most widely used and most eective evidence types for gene
prioritization type problems is that of Protein-Protein Internation (PPI) networks
[53],[12]. In this evidence type a graph is formed by considering each gene as a node,
and physical protein interactions between genes as edges. Creation of these networks
is often done via physically observing the movement of proteins by a method called
signal transduction. Considering the previously discussed DGAP principle of guilt-
by-association, PPI based methodologies allow for computational based techniques
to search for areas of interest based on things such as density. Specic use of PPIs in
the DGAP are explored in Chapter 4.
3.7.2 Co-expression
Genes under this evidence type are said to be related if they behave similarly across
dierent environments, i.e. cell type. The strength of co-expression is that it is
not biased to the highly studied genes, and as such can expose new and interesting
relationships between genes [57].
3.7.3 Phenotype
Phenotypical evidence is based on pairs of genes leading to the presentation of the
same phenotypes, i.e. hair colour or blood type. Often this evidence type is used
to strengthen already known relations. As a result, this evidence type is biased to
highly studied genes and their eects [57].
3.7.4 Functional Annotations
Functional annotation relations refer to genes which are involved in creation of par-
ticular phenotypes and serve the same function during the process. This evidence
type cane be though of as a low-level hybrid of both phenotypical and co-expression
based relations.
3.7.5 Text Mining
Text mining is based on the principles of meta analysis and seeks to relate genes that
are often mentioned in conjunction with each other. Typically, these approaches mine
databases of publications such as OMIM [29] via natural language methodologies. Of
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particular note for text mining is that it is among the rst large scale approaches taken
for the DGAP. Modern approaches however, often use text mining in conjunction with
the previously discussed evidence types.
3.8 Analysis and Benchmarking
As the success of a DGAP methodology is not directly related to the best relative
\score" produced, various post processing and benchmarking techniques have been
dened in the literature. The following subsections introduce three of the most com-
mon approaches.
3.8.1 Leave-One-Out Validation
Leave-One-Out (LOO) validation is the most common [43] approach to benchmark-
ing and focuses on whether a methodology is able to recover known genes during
execution. Formally, given N known disease related genes, x N-1 of these to be in
all candidate solutions. A LOO validation test is dened to be successful if the left
out gene is recovered by the method upon completion. This process is to be repeated
for all N genes [43].
3.8.2 Fold Enrichment
Fold enrichment is an extension to LOO and seeks to dene a pseudo-sensitivity
measure. A methodology has an m/n average fold enrichment, where if a LOO was
successful the technique correctly ranks known disease genes in the top m% for n%
of the known genes [74]. A fold enrichment is counted as a success if the previously
dened ratio is less than a dened threshold. This threshold often diers between
studies and methodologies and is left up to the choice of researchers.
3.8.3 Receiver-Operating Characteristic
Receiver-Operator Characteristic (ROC) is a second extension to LOO analysis and
denes a sensitivity measure based on True Positives (TP) and False Negatives (FN).
For a gene to be considered \found" and a TP its associated ranking must not exceed
a given threshold, otherwise it is labeled as a FN. The following equation describes
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the result of a ROC analysis:
Sensitivity =
TP
TP + FN
(3.1)
This type of analysis is often studied in classiers and presented in results to combat
algorithms which are easily fooled.
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Chapter 4
Literature Review
The purpose of this chapter is to provide a sample of the current study of the Dis-
ease Gene Association Problem (DGAP) and its associated literature. Section 4.1
discusses current biologically inspired techniques. Section 4.2 introduces a hybrid
bioinformatics approach which seeks to merge community detection and typical bio-
logical approaches. Finally, Section 4.3 introduces two modern community detection
approaches and discusses their relative strengths and weaknesses.
4.1 Biological Approaches
In previous biological studies of the DGAP and related problems, biologists have
commonly taken the route of increasing the accuracy of input datasets. Biologists
have also frequently applied methods to entirely new types of data sets, or attempted
to automate the entire process via a construction of a pipeline. An example of this
can be found in the paper by Lysenko et al. [48]. The system proposed in this paper
attempts to improve the accuracy of results by including additional evidence types
other than only protein-protein interactions. These additional evidence types include
but are not limited to co-expression relations and phenotype relations. While results
in the study by Lysenko et al. were favourable, the main technique used was that of a
random walk algorithm. Random walk algorithms in computer science are known for
being a rst step in testing whether a tness landscape has structure. As such, the
authors do mention that while their technique was not necessarily computationally
the strongest, that techniques in the future should include multiple evidence types to
build as much relational evidence as possible.
A second study by Sakthivel et al. [61] includes a more advanced computer science
technique than Lysenko et al. while remaining rmly biologically inspired. This
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comparative study tests the eectiveness of a clustering based single-objective genetic
algorithm technique across multiple distinct PPI disease data sets. While the authors
found the genetic algorithm technique highly eective, it did struggle compared to the
other standard approaches on diseases such as cerebral vascular disease. This could be
due to the genetic algorithm's method of exploration of the tness landscape having
a more dicult time nding viable solutions to build from. The authors discuss that
this relative diculty can come from how highly studied the already known disease
genes are. For example, breast cancer is more highly studied than generic cerebral
vascular diseases. To combat this, HGPEC [44] is a recently developed application
for Cytoscape (see Section 5.2.1) which seeks to rene the decision making process
for choosing known genes on a disease by disease basis. Though the plugin is based
on random walk based measures, the authors of the application report novel disease
gene relations discovered as a part of their case study of breast cancer.
Wu et al. [73] introduce an additional approach which seeks to rene PPI based
evidence via aggregating large amounts of standard PPI data together and building
a weighted network. This weighted network is then trimmed into smaller sub graphs
by selecting areas of dense weighting for continued analysis. As part of the study, the
authors tested their methodology on several cancer types, including breast cancer.
Signicant improvements over similar families of methodologies is reported not only
in accuracy, but also stability. Due to this, the authors speculate that their approach
to aggregation of PPI data into a weighted network is a notion that should be adopted
by future techniques.
Additional biological literature review eorts not contained in this section can be
found in the previous denition of the DGAP (Section 3.6), DGAP input data and
their various evidence type denitions (Section 3.7), and DGAP benchmarking tech-
niques (Section 3.8). Lastly, Table 5.4 contains several biological DGAP techniques
that will be used to measure the eectiveness of the methodology proposed by this
thesis.
4.2 Evolutionary Computation Approaches
In a study by Tahmasebipour and Houghten [66], the DGAP was adapted to an
evolutionary computation (EC) approach. The technique used by the authors was
that of a genetic algorithm (GA) based on the principles of community detection
(Section 2.1.14) problems. As such, candidate solutions in the GA took the form of
communities of potentially highly interacting genes. As part of the study both breast
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cancer and Parkinson's disease were investigated. Input data for these case studies
however only included PPI based evidence types. Favourable results were achieved
in comparison to the popular disease gene databases found in Table 5.4.
As a continuation of the previous study, Heravi and Houghten present a genetic
programming (GP) approach to the DGAP [30]. Additionally, the study adds two new
aspects to the family of EC approaches. The rst addition is the inclusion of multiple
evidence types in the data generation stage of the DGAP, while the second is the
introduction of centrality measures. By adding multiple evidence types the authors'
hope was to strengthen important relationships between genes that are not strictly
communicating on the protein level. This decision necessitated the introduction of
centrality measures being computed on given DGAP input networks due to data size
increases. The choice of which centrality measures to use is also briey explored in
the study. The authors conclude that the measures of stress and betweenness when
used in conjunction produced the strongest results. These results include a marked
improvement over the previous GA-based work on Parkinson's disease. However, the
technique was found to be slightly less eective when applied on the Breast Cancer
dataset. It is important to note that both case studies performed by the authors did
improve on popular known DGAP databases.
4.3 Community Detection Algorithms
As stated previously, there potentially exists merit in the EC based approach to
the DGAP for the introduction of advanced community detection techniques. One
such technique is that of the locus-based adjacency representation (LAR) [56]. This
chromosome implementation focuses on the ability of the candidate solution to possess
multiple communities, as well as vary in size. This ability not only comes from
encoding and decoding of the chromosome, but from modied genetic operators (i.e.
crossover). With this in mind, LAR has been shown to be an eective methodology
on benchmarking problems [58].
An extension to the LAR representation proposed by Liu et al. [46] introduces
a local search based genetic algorithm (GALS). This approach focuses on adapting
the typical mutation operator in a LAR based scheme to be more focused on making
local optimizations. Experimental results show that the technique is ecient as well
as highly eective.
Though these techniques are successful in their own right, the biological assump-
tions made as part of the DGAP nullify the main strength of these methodologies,
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namely, the ability of the candidate community size to grow and shrink arbitrarily
during evolution.
A second type of methodology is that of a multiobjective optimization approach.
As outlined in Section 2.2.8, the principle is to be maximizing two (or more) dierent
evaluations of individuals at the same time. This has been shown to be a successful
approach by Shi et al. [63], who employed a multiobjective approach to the commu-
nity detection problem. The objectives in the authors' approach were the in-degree
and out-degree of nodes in the network. With this in mind, the DGAP could poten-
tially show more accurate results if used in conjunction with advanced multiobjective
community detection approaches.
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Chapter 5
Methodology
As outlined in Section 4.2, there exists a chance to produce a novel system for pre-
dicting genes involved in various diseases. This novel system would be a hybrid of
biological and computer science approaches that takes into account multiple evidence
types and advanced multi-objective AI techniques. This new technique, however, will
still be inspired by the initial work of Tahmasebipour and Houghten [66]. Unlike the
work of Heravi et al. [30], this novel approach will use a genetic algorithm.
This proposed GA will be multi-objective, where each objective is the sum of the
centrality measures of each node across the community (see Section 5.1.6). Typical
multi-objective tness techniques like that of weighted sum require a value to be
placed on an objective. In the case of centrality measures as objectives this poses a
problem. For example, how can you decide if a higher \eigenvector" value is better
for a community than higher \betweenness" value? Surely values can be found ex-
perimentally, but this must be done for each graph, as not all graphs share the same
topology. This problem also eliminates the possibility of using a Pareto approach.
The argument against Pareto is constructed much the same as the one against a
weighted sum: what does it mean when looking at the Pareto front for an experiment
if one candidate community has more of one attribute than another? To be able to
construct a post processing of the Pareto front to give solutions to a biologist, these
questions need to be able to be answered.
This chapter seeks to discuss the various motivations of decisions made in this
thesis and dene the technique created completely. As such, genetic algorithm details
are found in Section 5.1, dataset choice and generation in Section 5.2, and nally
various evaluation criteria and benchmarking are discussed in Section 5.3.
31
5.1 Genetic Algorithm Details
This section and relevant subsections detail the internal structure of the Genetic
Algorithm created for the purposes of this thesis. As a whole, this technique was
implemented in the programming language Java version 10.0.1. All algorithms devel-
oped in this thesis were implemented directly, i.e. without the use of a package.
5.1.1 Individual Structure
The internal representation of a candidate solution will be that of a bitstring. Each
index in the bitstring will represent a gene, and a value of one at that index signals
that the gene being referenced is inside the community. The number of indices with
a value of one (true) in a chromosome is equivalent to the maximum community size
selected. Chromosomes will also possess a number of \xed genes" for LOO testing
(see Section 3.8.1). These genes, and as such their indices in the bitstring, will always
be made to be true. Implementation will be achieved through the Java BitSet data
structure available in the Collections library.
5.1.2 Self Correction
If through genetic operators a chromosome ends up not possessing the maximum
community size, the individual must undergo self correction. Self correction occurs
in three total cases. The following subsections introduce each respective correction
procedure. Note that these operations can lead to destructive behaviour and are
brought about entirely through genetic operators. This is discussed further in Section
5.1.5.
Missing Fixed Genes
Through exchange operators it is possible in numerous cases that the known disease
genes are missing from the children. Self correction is simply achieved by setting the
xed gene indices to be true. Note that this can lead to the community size being
larger than the maximum and as such performs the procedure in the next subsection
immediately.
Over Community Maximum Size
If the chromosome possesses more genes in the candidate community than the maxi-
mum, the process of self correction will randomly remove genes from the community
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until the size is correct. Note that the randomly removed genes cannot be the xed
genes.
Under Community Maximum Size
If a candidate community is under the maximum community size limit, random new
genes are added until the xed size is again reached.
5.1.3 Selection
For the purposes of this thesis, all selection is implemented via tournament selection.
For full denition see Section 2.2.5.
5.1.4 Mutation
Original implementations of a mutation operator were inspired by that of single-bit
mutation. This technique selects a random index and ips the state found there.
However, this can lead to numerous amounts of self corrections for an individual.
For example, if a known gene is set to false, a self correction is incurred. As a
result, the mutation operator used in this thesis is an extension of a basic single-bit
mutation, exchange mutation. Exchange mutation is achieved by randomly selecting
one non-xed true index in the bitstring, and randomly selecting one false index in
the bitstring. These two indices then have their states inverted thus preserving the
maximum community size and incurring no self corrections as a result of mutation.
5.1.5 Crossover
This thesis incorporates the use of two crossover methods. The following two subsec-
tions dene their procedure and discuss their strengths and weaknesses.
One-Point Crossover
The rst method is that of a standard one-point crossover. For this method two
individuals are chosen via the selection operator, as well as a random index i. From
indices [0; i), the individuals remain the same. Indices from [i; N ] (where N is the
bitstring length) have their values swapped between individuals. While this method
encourages strong exploration of the tness landscape, it can be quite destructive to
the chromosome. There are numerous cases in which random selection of i can incur
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self correction and damage strong genetic material meant to be passed on to future
generations.
Safe Dealer-Based Crossover
To combat self correction, a second crossover technique named Safe Dealer-Based
Crossover (SDB) has been created. SDB is achieved by rst selecting two individuals
and nding the intersection of their true indices inside of the bitstrings. The two
children of the method are then initialized with these intersections also set as true.
Next, all of the true indices that the parent chromosomes do not have in common are
stored in a list data structure and shued. Finally, for each item in the list, evenly
distribute values to be set as true to the children. Upon completion, each child
should have exactly the maximum community size with no self corrections necessary.
One downside to this methodology is that it can potentially lower the amount of
exploration of the tness landscape. This is due to new indices never being created,
only \passed" between individuals. As such, for SDB to be successful it relies on large
population.
5.1.6 Fitness Methodology
In Section 2.2.8), various issues and reasoning for the exclusion of a Pareto based
tness scheme were presented. This section introduces another multi-objective tness
technique known as Sum of Ranks (SoR) [4][15]. SoR diers from other popular multi-
objective techniques such as NSGA-II [16] and SPEA2 [76] as SoR does not create or
maintain a Pareto front. Instead, the returned values of executing the SoR method
on a population are the relative ranks of each individual to the population as a whole.
Consequently, measuring the raw ranks of the individuals for any reason is no longer
viable as ranks are only relative within a generation. However, SoR is not entirely
without benets. Consider the example of a small test population in Tables 5.1, 5.2,
and 5.3. Table 5.1 contains the raw values of six individuals and their associated
Pareto ranking. Table 5.2 contains SoR taking place. In this table, each objective
is linearly ranked by raw tness. Then for each individual, the sum of their ranks
is computed. Finally, each individual is then re-ranked by this summed value. The
resulting ranking is taken to be the output of the SoR technique.
Clearly as stated previously, this does not create a Pareto front of solutions. This
is perfect for the proposed technique as no extra post processing must be done about
what centrality measures to possibly sacrice for a \good" choice to be made. Further
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Raw Fitness Pareto
Indiv A B C D Rank
1 1 9 5 4 1
2 2 100 4 8 1
3 10 9 9 10 2
4 16 100 8 4 2
5 16 9 500 0 1
6 0 1000 1000 1000 1
Table 5.1: Pareto ranking example with six individuals
value can be found in that no adjustment to standard methods of tness selection
must be done to t SoR into a GA. It is entirely safe to return to basic premises such
as tournament selection.
Like most modern techniques in evolutionary computation, there exist numerous
small adjustments that can be made to SoR to improve performance and results. For
example, Table 5.3 shows a variant known as normalized SoR. This diers from stan-
dard SoR only by normalizing the rank values obtained from the previous steps. The
advantage of this optimization lies in that of eliminating issues of individuals having
widely varying yet highly clustered scores resulting in ties. Note the implication that
all objectives are balanced fairly despite potential diversity in ranks.
With these properties in mind, SoR becomes a very strong and clear choice for
use in the proposed technique as it is easily extended to more dimensions, allows for
the use of other standard techniques (selection, etc), and most importantly accounts
for the wide variety of raw values that may be found in a multi-objective problem.
As such, this thesis will employ the use of normalized SoR in all experiments. Raw
values for each objective will be computed by the summation of each gene's respective
centrality measures that are being maximized if they are inside of the candidate
community. The generation of centrality measures for each gene is described in Section
5.2.
5.2 Datasets and External Tools
In an eort to remain consistent with previous work, both Breast Cancer and Parkin-
son's disease will be studied in this thesis. Additionally, used datasets will extend to
that of Alzheimer's disease. Generation of these data sets is outlined in Section 5.2.1
and remains true to Heravi et al. [30].
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New Ranks Sum of Pareto
Indiv A B C D Ranks Re-ranked Rank
1 2 1 2 2 7 1 1
2 3 2 1 3 9 2 1
3 4 1 4 4 13 4 2
4 5 2 3 2 12 3 2
5 5 1 5 1 12 3 1
6 1 3 6 5 15 5 1
Table 5.2: Sum of ranks example with same six individuals as in Table 5.1
Normalized Ranks Sum Sum
Indiv A B C D Norm Re-ranked Ranks
1 0.4 0.33 0.33 0.4 1.46 1 1
2 0.6 0.66 0.16 0.6 2.03 2 2
3 0.8 0.33 0.66 0.8 2.6 5 4
4 1 0.66 0.5 0.4 2.56 4 3
5 1 0.33 0.83 0.2 2.36 3 3
6 0.2 1 1 1 3.2 6 5
Table 5.3: Normalized sum of ranks examples with same six individuals as in Tables
5.1 and 5.2
5.2.1 Dataset Generation Process
Initially, xed known disease genes are selected via the Genotator [70] tool. Genotator
is a tool used by biologists to aggregate data and make it easier to search and index.
In the case of this thesis, the top fteen genes are always selected as known. Note
that these also become the benchmarking criteria for LOO (leave one out) analysis
(see Section 3.8.1). Next, these known genes are input into Cytoscape [14]. Cy-
toscape is open source software which allows for the study of genetically inspired
networks. GeneMANIA [71] is a plugin for Cytoscape which predicts relationships
between genes. It accomplishes this by building a complex network via the various
available evidence types (PPI, pathway, etc). In this thesis, given fteen known dis-
ease genes from Breast Cancer, GeneMANIA allows the querying of the next N most
frequently interacting genes based on evidence types and stores the resulting network
in a Cytoscape structure. Evidence types for this work include physical interactions
(PPI), co-expression evidence, phenotype based relations, functional annotations, and
predicted relationships via text mining. Lastly, the CentiScaPe [62] plugin is used.
This allows the Cytoscape software to compute various centrality measures based on
the currently open graph and export the results. Exporting is done simply to a csv
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Name Evidence Types
CIPHER phenotype, PPI [74]
ENDEAVOUR expression, PPI, functional, text mining [1]
GFINDER phenotype, expression [50]
CAESAR expression, functional, text mining [24]
CGPRIO sequence, functional, PPI [74]
GENESEEKER expression, functional, text mining, phenotype [68]
Table 5.4: Popular DGAP methodologies and their respective evidence type usage
le, and is then fed as input into the GA.
5.3 Evaluation Criteria
Biological parameters as well as various GA parameters will be chosen such that
comparison can be made with previous bodies of work. In addition, all three test-
ing procedures from Section 3.8 will be implemented so as to review the proposed
methodology as thoroughly as possible. Particular attention will be given to the re-
sults of LOO validation during empirical testing as successful runs can be examined
individually. Table 5.4 contains additional popular DGAP methodologies and will be
used to compare with the new technique outlined in this thesis.
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Chapter 6
Breast Cancer Case Study
Breast Cancer is a potentially hereditary type of cancer which typically begins with
tumors growing in breast tissue. In general, the prognosis for the disease is highly
dependant on the nature of the cancer, extent of spreading to other organs, as well
as the individual's age [25]. Despite this, recent scientic advances have lead to a
signicantly improved prognosis of this disease. This chapter contains a case study of
Chapter 5's methodology applied to the disease of Breast Cancer. This disease was
chosen due to its highly studied nature, allowing for greater possibility of drawing
accurate conclusions.
6.1 Data Generation
Data generation for this case study is performed as described in Section 5.2.1. Table
6.1 contains the known genes for breast cancer. These known genes are kept equivalent
to previous work so as to allow for easy comparison.
6.2 Experimental Design
For the purposes of this case study, three individual parameter settings were empir-
ically chosen in line with previous work to test the eectiveness of the methodology
presented by this thesis. Table 6.2 contains the \HighCross" (high crossover) param-
eter setting, while Tables 6.3 and 6.4 contain the settings for \Balance" (balanced
crossover and mutation) and \HighMut" (high mutation) respectively. Note that
Tables 6.3 and 6.4 contain only the changes from the default parameter setting of
HighCross. Fitness objective choice is discussed in the following section.
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Gene NCBI ID
BRCA1 672
AR 367
ATM 472
CHEK2 11200
BRCA2 675
STK11 6794
RAD51 5888
PTEN 5728
BARD1 580
TP53 7157
RB1CC1 9821
NCOA3 8202
PIK3CA 5290
PPM1D 8493
CASP8 841
Table 6.1: Breast Cancer Known Disease Genes
Parameter Value
Population 8000
Generations 2500
Selection Tournament, k=5
Elitism 1
Crossover Method One-point
Crossover % 75%
Mutation % 25%
Runs 30
Community Size 100
Fitness Method SOR
Table 6.2: HighCross parameter setting
Parameter Value
Crossover % 50%
Mutation % 50%
Table 6.3: Balance parameter setting
Parameter Value
Crossover % 30%
Mutation % 70%
Table 6.4: HighMut parameter setting
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Measures Radiality Betweenness Bridging Centroid Closeness Degree Eccentricity Eigenvector Stress
Radiality - 0.85 -0.48 0.99 0.99 0.94 0.31 0.92 0.88
Betweenness 0.85 - -0.31 0.89 0.89 0.91 0.28 0.84 0.98
Bridging -0.48 -0.31 - -0.50 -0.50 -0.58 -0.21 -0.63 -0.41
Centroid 0.99 0.89 -0.50 - 0.99 0.95 0.32 0.94 0.90
Closeness 0.99 0.89 -0.50 0.99 - 0.98 0.33 0.95 0.92
Degree 0.94 0.91 -0.58 0.95 0.98 - 0.34 0.97 0.95
Eccentricity 0.31 0.28 -0.21 0.32 0.33 0.34 - 0.35 0.32
Eigenvector 0.92 0.84 -0.63 0.94 0.95 0.97 0.35 - 0.90
Stress 0.88 0.98 -0.41 0.90 0.92 0.95 0.32 0.90 -
Table 6.5: Correlation study from Breast Cancer data
6.3 Fitness Objectives
The purpose of this section is to illustrate the decision making process for selecting
tness objectives.
6.3.1 Correlation Study
In an eort to fully understand which centrality measures should be used as tness
objectives, a brief correlation study was performed on the breast cancer dataset as a
precursor to potentially using principle component analysis. Samples were formed by
grouping numerical results from each centrality measure together as found in Section
2.1.3. Correlation was then computed using a standard Pearson correlation coecient
[3]. Table 6.5 contains the results of this study.
Understanding why eccentricity possessed a low correlation coecient yet was
unfavoured by previous methods can be found in the raw data. Across all 2015 nodes
in the graph, only four values appeared (0.3, 0.5, 0.25, and 0.75). This illustrates why
previous studies found eccentricity to be lacking, as well as accounting for the lower
correlation coecients across the table. Placing the actual complex network into
visualization software reveals why eccentricity failed to report varied values. Several
nodes exist as outliers to the network. This gives each node in the network a far
distant node to travel to, producing practically static values. This is a practical
example of the limitations of eccentricity much like is specied in Section 2.1.13.
Particular note should be made of the correlation existing via stress and between-
ness. With stress and betweenness possessing a correlation of 0.98, it presents as
counter-intuitive that previous work (see Section 4.2) would identify that these two
measures working in conjunction produce the most successful results. As a result,
the following subsection will include an eort to replicate the success of these two
measures in a purely multi-objective environment. Additionally, bridging will also
be a focus of preliminary testing as it presents fairly low negative correlations with
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Figure 6.1: Bridging and betweenness LOO validation parameter setting comparison
on one-point crossover
respect to all other centrality measures.
6.3.2 Preliminary Fitness Testing
Figure 6.1 illustrates the success rates of Leave-One-Out (LOO) validation based on
GA parameters dened in Section 6.2 on the hypothesized multi-objective setting of
bridging and betweenness. Unsurprisingly, the HighCross parameter setting performs
worse in all validation cases due to the destructive nature of one-point crossover for
this methodology's representation. Going forward, results in following experiments
will include Safe Dealer-Based (SDB) crossover (see Section 5.1.5) for comparison
with the same parameter settings dened in Section 6.2.
As such, Figure 6.2 contains the comparison of three dierent objective schemes
using the Balance parameter setting. Based on this gure, it is straightforward to see
that the objective setting of stress and betweenness produces the strongest results.
Note that despite the dierences in approach (see Section 4.2), these two path based
measures working together have been replicated to be highly successful despite their
extremely high correlation. Other tness objective settings were investigated, but are
left out of this thesis due to the completely dominant results given by the objectives
found in Figure 6.2. However, raw summary results of these experiments can be found
in Section A.1.
For the sake of brevity, Table 6.6 denes labels for the objective settings that will
be explored as part of this work. These labels are designed to be used in conjunction
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Figure 6.2: Comparison of LOO validation successes on breast cancer using one-point
crossover on the Balance parameter setting
Label Objective(s)
Base Bridging, Betweenness
Three Degree, Bridging, Betweenness
AK Stress, Betweenness
sBet Betweenness
sStress Stress
Table 6.6: Fitness objective labeling scheme
with the parameter settings dened in Section 6.2. For example, results dened by the
label \AK-Balance" imply a tness objective setting of stress and betweenness with
EC parameters specied in Table 6.3. The inclusion of the single-objective settings
sBet and sStress is in hopes of validating the use of a multi-objective methodology.
6.4 Experimental Results
Figures 6.3 and 6.4 contain example convergence curves for AK-Balance experiments
using one-point and SDB crossover respectively. Note that regular convergence curves
using the Sum of Ranks (SOR) methodology are not possible due to the tness of
individuals always being relative to each epoch. As a result, data points in these
gures are the raw objective scores of the best individual at each generation. These
raw values are then normalized for easier visualization as the numerical values of
various centrality measures can vary widely with respect to one another.
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Figure 6.3: Breast cancer AK-Balance with one-point crossover experiment tness
curve
Figure 6.4: Breast cancer AK-Balance with SDB crossover experiment tness curve
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Setting LOO Sensitivity Avg. Best FE Avg. Median FE
Three-Balance 12/15 0.80 678.29 35.13
Three-HighCross 13/15 0.87 712.45 18.43
Three-HighMut 12/15 0.80 578.91 66.23
Base-Balance 13/15 0.87 729.33 32.08
Base-HighCross 12/15 0.80 736.54 18.43
Base-HighMut 12/15 0.80 578.01 72.65
AK-Balance 15/15 1.00 1092.99 87.96
AK-HighCross 15/15 1.00 1137.39 46.68
AK-HighMut 15/15 1.00 1062.76 126.35
sBet-Balance 15/15 1.00 1243.21 91.26
sStress-Balance 14/15 0.93 831.25 72.49
Table 6.7: Breast cancer with one-point crossover experiment summary
Figure 6.3 illustrates a fairly standard convergence for an EC technique, while
Figure 6.4 shows an extremely fast convergence rate. While not necessarily always a
detriment, a convergence of this type can often mean lack of diversity in a population
due to either selection pressure being too high, or the actual exchange of genetic
material between individuals being limited during evolution. This issue is further
explored in Section 6.7 with reference to specic performance measures.
Tables 6.7 and 6.8 contain study-wide summaries of each experiment type based
on the evaluation criteria dened in 5.3. Note that fold enrichments (FE) measures
are computed on one set of thirty samples, one gene at a time, before being aggregated
into a list to nd the best and median values and are then averaged with higher values
representing better performance. Single objective settings do not include HighCross
and HighMut due to the Balance setting possessing completely dominant results.
From these results, it is apparent that the SDB crossover is signicantly less
eective for this problem as even the worst one-point setting out performs the best
SDB approach in terms of sensitivity. However, it still interesting to note that some
SDB settings produce a higher FE. This is likely due to the fact that SDB crossover,
while less eective, is considerably more stable and converges more quickly. Individual
gene success rates for SDB crossover are found in Section A.1.
Based on Table 6.7, the most successful measures for this case study are the
sBet-Balance setting, and the AK tness scheme due to their result of recovering all
fteen known LOO validation genes. Tables 6.9 and 6.10 contain the individual gene
success rates and statistics for both AK-Balance and sBet-Balance respectively, with
the \LOOs" column representing the number of total LOO validation successes. AK-
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Setting LOO Sensitivity Avg. Best FE Avg. Median FE
Three-Balance 8/15 0.53 875.56 57.88
Three-HighCross 8/15 0.53 837.33 47.86
Three-HighMut 8/15 0.53 790.59 58.17
Base-Balance 8/15 0.53 832.42 61.62
Base-HighCross 8/15 0.53 870.22 58.00
Base-HighMut 8/15 0.53 827.00 61.02
AK-Balance 11/15 0.73 1333.39 83.79
AK-HighCross 10/15 0.67 1333.33 75.37
AK-HighMut 10/15 0.67 1035.56 94.50
sBet-Balance 11/15 0.73 1352.38 127.24
sStress-Balance 9/15 0.60 1133.33 82.08
Table 6.8: Breast cancer with SDB crossover experiment summary
Balance has been selected from its family of settings as it possesses both the second
best average FE, and second best median FE. In these tables, if a tie exists between
two or more genes, the next place gene is incremented accordingly. For example, if
there is a 14-way tie for rst place, second place is then technically awarded 15th
place.
Surprisingly, despite the multi-objective scheme possessed by AK-Balance, sBet-
Balance appears to successfully rank the known genes higher in the best cases. How-
ever, both settings appear to struggle with similar genes, namely STK11 and PPM1D.
Further discussion and comparison can be found in Section 6.7.
6.5 Comparison to Previous Work
Table 6.11 shows the comparison between two non-EC methodologies as well as the
two EC techniques on which this thesis is based.
Clearly the technique proposed in this thesis is an improvement on past techniques
as all fteen known LOO validation genes have been recovered. Additionally, average
median FE has more than doubled in both cases. Section 6.7 contains discussion as
to why this may be the case.
6.6 Predicted Genes
As the overall goal of the DGAP is predict new genes for study, the top 1% of non-
xed genes across the AK-Balance and sBet-Balance experiments were examined.
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Gene Best Rank Median Rank Mean Rank Std Rank LOOs
BRCA1 15 19.50 20.73 6.65 30
BRCA2 23 76.50 83.27 37.44 16
TP53 1 23.00 29.40 18.49 30
AR 27 88.50 176.27 146.14 9
ATM 15 72.00 111.83 119.40 25
CHEK2 31 74.50 104.70 94.81 22
STK11 68 213.50 254.83 139.50 1
RAD51 15 56.50 76.73 97.57 27
PTEN 30 188.00 221.47 134.91 11
BARD1 15 39.50 52.73 62.25 29
RB1CC1 15 60.50 96.37 100.57 20
NCOA3 15 34.00 42.60 24.37 29
PIK3CA 1 22.50 23.27 7.51 30
PPM1D 59 258.50 266.87 142.39 2
CASP8 15 83.50 130.00 130.03 21
Table 6.9: AK-Balance parameter setting with one-point crossover individual gene
statistics on breast cancer
Gene Best Rank Median Rank Mean Rank Std Rank LOOs
BRCA1 1 25.00 25.53 9.92 30
BRCA2 15 65.50 71.07 36.91 15
TP53 1 20.50 19.17 5.54 30
AR 1 85.50 100.47 87.10 13
ATM 1 40.50 46.23 26.39 30
CHEK2 20 83.00 103.17 86.08 21
STK11 33 220.00 255.23 150.55 7
RAD51 15 50.00 83.97 104.83 26
PTEN 32 112.50 174.47 142.91 12
BARD1 1 35.00 36.30 15.33 30
RB1CC1 1 76.50 115.00 128.79 19
NCOA3 1 31.00 32.93 15.59 30
PIK3CA 15 21.00 22.53 8.61 30
PPM1D 22 214.50 245.87 151.37 3
CASP8 1 56.00 102.17 107.86 21
Table 6.10: sBet-Balance parameter setting with one-point crossover individual gene
statistics on breast cancer
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Approach Avg. Median FE LOO Sensitivity
CIPHER 25 10/15 0.67
Past GA Approach 30 12/16 0.80
GP Approach 24 9/15 0.60
AK-Balance 88 15/15 1.00
sBet-Balance 91 15/15 1.00
Table 6.11: Breast cancer DGAP methodology comparison. Balance methods imple-
ment the one-point crossover technique.
Gene Description
APP Amyloid beta precursor protein
PIK3R1 Phosphoinositide-3-kinase regulatory subunit 1
EP300 E1A binding protein p300
CHEK1 Checkpoint Kinase 1
RFC3 Replication Factor C Subunit 3
PCNA Proliferating Cell Nuclear Antigen
Table 6.12: Predicted genes for future breast cancer study.
Table 6.12 contains a subset of these selected genes conrmed by Genotator to have
known interactions with breast cancer.
Of particular note from these genes are APP and EP300. APP is typically thought
to be a gene involved in the presentation of Alzheimer's disease as it is often found in
brain and spine tissues. Furthermore, even small mutations in this gene often lead to
early onset Alzheimer's disease [52]. Interestingly, recent studies have begun to study
its relevance to the onset of breast cancer [45] conrming the previous prediction.
EP300 is often seen regulating cell growth and division and as such has already been
conrmed to be linked to various dierent types of cancer [52].
6.7 Case Study Discussion and Conclusions
Originally, the hypothesis proposed in Chapter 5 and then rened in Section 6.3.2 of
this chapter was that a multi-objective methodology containing the centrality mea-
sure of bridging (Section 2.1.12) would produce the strongest results. The motivation
for this decision came from examining the correlation between pairs of measures and
determining that bridging in conjunction with any other measure provided at least
some amount of not highly correlated data. Despite these facts, this case study has
shown and conrmed that the previous literature was correct to use stress and be-
tweenness together (AK tness schemes) when studying breast cancer. Furthermore,
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using just stress or betweenness on their own in a single-objective environment was,
for this case study, able to produce improved results. Another contradiction given
by the results of this study was the overall predicted performance of SDB crossover.
The original motivation behind this crossover was to avoid the numerous self correc-
tions behind breeding new individuals if one-point crossover was in use. Use of SDB
resulted in lowered sensitivity rates across all testing conditions. However, it was
found to produce higher FE values for this case study. This is likely due to the highly
exploitative nature of the technique. Since it does not create \new" information and
only exchanges data between chromosomes, the technique is considerably less explo-
rative. This is reected in how quickly the technique converges (see Figure 6.4) in
comparison to a one-point crossover approach even with such a large population size.
As stated previously, the path based measures of stress and betweenness used both
in conjunction or on their own yielded signicant improvements over past approaches
(see Section 6.5). These improvements include the recovery of each known LOO
validation gene. This success is likely to do with integration of multiple evidence
types, as well as the exchange mutation approach used by this thesis being a strong
hybrid of both exploration and exploitation. In the future to improve the recovery rate
of the challenging genes in this problem (STK11 and PPM1D), more shortest path
based measures should be explored. Furthermore, SDB crossover as a methodology
should be rigorously empirically tested and iterated upon to balance its exploitative
nature.
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Chapter 7
Parkinson's Disease Case Study
Parkinson's disease is a genetic disease which leads to the degeneration of the nervous
system [59]. Typical symptoms of Parkinson's include tremors, impaired balance,
and communication diculties [33]. As a result of the degeneration of the nervous
system, individuals with Parkinson's have a reduced life expectancy. Parkinson's is
also known to be a particularly complex disease with numerous genetic interactions.
This chapter applies the methodology dened in Chapter 5, as well as the rened
changes from Chapter 6 to Parkinson's disease in order to measure the eectiveness
of the introduced methodology.
7.1 Data Generation
Input data for this case study is generated as dened in Section 5.2.1. Known genes,
listed in Table 7.1, are taken from previous work to allow for various comparisons.
7.2 Experimental Design
Parameter settings as well as tness objective labels are kept consistent with the
naming convention outlined in Section 6.3.2. For the purposes of this case study, all
settings are repeated.
7.3 Experimental Results
Figures 7.1 and 7.2 contain convergence curves for AK-Balance experiments on one-
point and SDB crossover respectively. Data points are computed corresponding to the
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Gene NCBI ID
LRRK2 120892
SNCA 6622
PARK2 5071
MAPT 4137
APOE 348
GBA 2629
GAK 2580
BST1 683
DRD2 1813
PINK1 65018
MAOB 4129
BDNF 627
CYP2D6 1565
PON1 5444
COMT 1312
Table 7.1: Parkinson's Known Disease Genes
previous case study. As such, each curve represents the change of the best individual's
raw objective values over time, then normalized.
Similarly to the previous chapter, the one-point crossover experiment's curve be-
haves much as a typical EC technique tends to behave, with a gradual build-up over
time. SDB crossover possesses the behaviour of an experiment that either has ex-
cessive selection pressure, or potentially a methodology that favours exploitation too
heavily. As discussed in Section 6.7, this behaviour is almost certainly the result of
how SDB crossover functions as a result of not creating \new" information strictly
Figure 7.1: Parkinson's AK-Balance with one-point crossover experiment tness curve
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Figure 7.2: Parkinson's AK-Balance with SDB crossover experiment tness curve
Setting LOO Sensitivity Avg. Best FE Avg. Median FE
Three-Balance 8/15 0.53 677.81 409.69
Three-HighCross 9/15 0.60 449.29 404.39
Three-HighMut 8/15 0.53 656.16 426.45
Base-Balance 8/15 0.53 723.99 405.51
Base-HighCross 8/15 0.53 647.72 404.35
Base-HighMut 8/15 0.53 586.14 417.82
AK-Balance 12/15 0.80 1276.49 508.05
AK-HighCross 13/15 0.87 1427.95 486.99
AK-HighMut 12/15 0.80 1203.65 664.49
sBet-Balance 12/15 0.80 1402.37 512.99
sStress-Balance 13/15 0.87 1150.58 500.15
Table 7.2: Parkinson's with one-point crossover experiment summary
through the breeding process.
Tables 7.2 and 7.3 contain experiment summaries for both one-point and SDB
crossover respectively. Measures are computed as outlined in the previous case study,
described in Section 6.4.
It is immediately evident based on Tables 7.2 and 7.3 that, despite the overall suc-
cess of the methodology, Parkinson's disease presents a greater challenge than breast
cancer for the problem of disease gene association. However, the relative performance
between settings mirrors that of breast cancer. In particular, the hypothesized per-
formance of bridging is lower than expected, and also the single-objective settings
perform extremely well. Furthermore, SDB crossover is again, even in the best case,
out performed by some of the worst case one-point crossover parameter settings. One
interesting dierence between case studies is that the average median FE values ap-
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Setting LOO Sensitivity Avg. Best FE Avg. Median FE
Three-Balance 6/15 0.40 977.78 429.36
Three-HighCross 6/15 0.40 906.00 420.88
Three-HighMut 6/15 0.40 591.03 430.63
Base-Balance 5/15 0.33 805.96 417.31
Base-HighCross 6/15 0.40 716.83 317.04
Base-HighMut 5/15 0.33 820.00 424.29
AK-Balance 8/15 0.53 1234.29 365.71
AK-HighCross 8/15 0.53 1087.33 463.43
AK-HighMut 8/15 0.53 1106.98 474.71
sBet-Balance 6/15 0.40 1200.00 467.83
sStress-Balance 8/15 0.53 1333.33 490.63
Table 7.3: Parkinson's with SDB crossover experiment summary
pear to be higher across all parameter settings in comparison to those for breast
cancer. This is likely tied to individual gene rankings, with some being signicantly
easier to identify than others. Tables 7.4 and 7.5 contain individual gene rankings and
performance measures. One-point crossover versions of AK-HighCross and sStress-
Balance have been selected as they recover the highest number of the known LOO
validation genes. Summary statistics for the remaining objectives are available in
Appendix A.2.
Much like the previous case study, Tables 7.4 and 7.5 illustrate that some of the
genes are more dicult than others to recover. For Parkinson's disease, these include
CYP2D6, GAK, COMT, and APOE. In the case of LRRK2 and GBA, the methodol-
ogy did not recover them at all. The remaining LOO validation genes however appear
to be extremely stable. Interestingly, the approximate diculty of these genes appears
to be mirrored in the sStress-Balance parameter results. Section 7.6 further discusses
diculty comparisons between case studies, and known gene diculty within case
studies.
7.4 Comparison to Previous Work
Table 7.6 contains a comparison between past EC approaches as well as a popular
biologically inspired DGAP approach, ENDEAVOUR.
Much like in the previous case study, the technique proposed by this thesis out
performed past methodologies in terms of sensitivity and FE. Note, a large portion of
the success of this methodology in terms of FE is due to the overall stability obtained
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Gene Best Rank Median Rank Mean Rank Std Rank LOOs
CYP2D6 197 370.00 355.33 43.50 1
GAK 15 357.50 268.20 134.67 5
MAOB 15 22.50 30.83 31.75 26
PON1 15 123.00 160.80 130.72 22
COMT 28 358.50 264.43 141.04 8
GBA 287 370.50 368.87 18.45 0
BST1 15 48.00 84.10 100.20 27
DRD2 15 19.00 18.50 3.17 30
LRRK2 67 364.00 347.93 58.56 0
MAPT 15 303.00 218.83 157.94 14
PINK1 15 52.50 105.87 107.57 26
APOE 22 119.50 197.40 148.49 9
BDNF 22 98.50 149.63 130.19 16
PARK2 1 15.00 11.20 6.88 30
SNCA 1 15.00 12.57 6.47 30
Table 7.4: AK-HighCross parameter setting with one-point crossover individual gene
statistics on Parkinson's
Gene Best Rank Median Rank Mean Rank Std Rank LOOs
CYP2D6 83 425.50 377.13 103.39 1
GAK 81 410.50 324.43 136.42 2
MAOB 15 21.50 37.87 30.77 21
PON1 26 94.00 165.07 150.37 16
COMT 36 421.50 331.30 138.53 3
GBA 336 430.00 429.07 23.56 0
BST1 1 31.50 53.67 81.84 29
DRD2 1 18.50 17.63 4.16 30
LRRK2 348 427.50 428.50 21.41 0
MAPT 25 265.50 246.00 177.65 10
PINK1 1 39.50 65.87 101.67 28
APOE 18 206.00 253.37 167.85 5
BDNF 33 152.50 187.93 129.63 5
PARK2 1 15.00 13.73 4.68 30
SNCA 1 15.00 13.17 6.06 30
Table 7.5: sStress-Balance parameter setting with one-point crossover individual gene
statistics on Parkinson's
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Approach Avg. Median FE LOO Sensitivity
ENDEAVOUR 11.11 3/15 0.20
Past GA Approach 18.33 5/15 0.33
GP Approach 22.22 6/15 0.40
AK-HighCross 486.99 13/15 0.87
sStress-Balance 500.15 13/15 0.87
Table 7.6: Parkinson's DGAP methodology comparison. Balance method implements
the one-point crossover technique.
Gene Description
APP Amyloid beta precursor protein
NTRK2 Neurotrophic Receptor Tyrosine Kinase 2
UBC Ubiquitin C
C8A Complement C8 Alpha Chain
LECT2 Leukocyte Cell Derived Chemotaxin 2
Table 7.7: Predicted genes for future Parkinson's study.
due to the ease of ranking several of the known LOO validation genes. Section 7.6
contains further discussion as to how the problem of disease gene association diers
in diculty for Parkinson's relative to the previous case study.
7.5 Predicted Genes
Maintaining the overall goal of the DGAP, the top 1% of non-xed genes across
both the AK-HighCross and sStress-Balance parameter settings were investigated.
Table 7.7 contains the noteworthy genes conrmed to have known interactions with
Parkinson's by Genotator.
Interestingly, the APP gene is again identied by the methodology as particularly
guilty. As stated previously, the APP gene is often found in brain and spine tissues
so it comes as no surprise that there already exists links between this gene and the
neurodegenerative properties of Parkinson's disease [18]. Second, NTRK2 is typi-
cally responsible for maturation and development of various central nervous system
properties such as synapse formation. This gene is often associated with epilepsy,
however recent studies have conrmed its involvement with Parkinson's disease [65].
Additionally, the C8A and UBC genes have been previously identied by past EC
approaches as being guilty by association [31].
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7.6 Case Study Discussion and Conclusions
Parkinson's presents a unique challenge due to the relatively balanced diculty of the
known genes. Despite this more challenging nature, the results presented in this case
study mirror that of the breast cancer case study, namely, the weak results of SDB
crossover. As stated previously, the weaker performance of SDB crossover appears to
be due to the lack of exploration and heavy exploitation principles in the approach.
A second similarity is that of the strength of the path based objective settings of
AK and sStress. However, despite the strength of these methodologies not all genes
were recovered. In an eort to investigate this, the raw values of the troublesome
genes (i.e. GBA) were inspected. In the case of each missed gene, the raw centrality
measure values of stress and betweenness were at best approaching the mean or lower.
This inspection was also repeated for the troublesome genes from the previous case
study's dataset, and conrmed the same behaviour. This implies that stress and
betweenness in some cases is not enough to see how important a gene's role is in a
network. Future studies should thus investigate more shortest path based measures.
A signicant dierence between case studies is the highly increased FE values
across all parameter settings. One potential reason for this increase is that the
methodology is very stable on the genes it manages to recover. This can be seen
in Table 7.5 and inspecting the standard deviation of the ranks for the genes which
are recovered all thirty times. Even in the case of some of the dicult genes, the
standard deviation is quite low. In the future, more performance metrics should be
introduced to measure stability.
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Chapter 8
Alzheimer's Disease Case Study
Alzheimer's disease is a long term degenerative disease which aects the brain. Typi-
cal symptoms include loss of short-term memory, mood swings, language deciencies,
and eventual sustained dementia. Long term eects of the disease typically result in
loss of bodily functions, and eventually death. Despite the deadly nature of the dis-
ease, it is still largely poorly understood [10]. As part of a continued eort to test the
methodology dened in this work, this chapter contains a case study of Alzheimer's
disease based on principles learned from Chapters 5, 6, and 7.
8.1 Data Generation
Data generation for this case study is based on the procedure outlined in Section 5.2.1.
However, Genotator does not possess database entries for Alzheimer's disease. As
such, the selection process for nding known genes must be accomplished another way.
The Online Mendelian Inheritance in Man (OMIM) database is an online resource
for aggregating human genome data with a focus on genetic disorders [29]. Table 8.1
contains the known Alzheimer's genes as dened by OMIM. These genes are then
used as input to Cytoscape, and the data generation continues as normal. Note that
as this is a less rigorous process than the previous case studies, the known genes have
been selected in a conservative manner.
8.2 Experimental Design
Parameter settings and tness objective labels are kept consistent with the naming
convention outlined in Section 6.3.2 and are repeated as part of this case study.
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Gene NCBI ID
HFE 3077
NOS3 4846
PLAU 5328
A2M 2
MPO 4353
APP 351
PSEN1 5663
PSEN2 5664
APOE 348
Table 8.1: Alzheimer's Known Disease Genes
Figure 8.1: Alzheimer's AK-Balance with one-point crossover experiment tness curve
However, for the sake of brevity, only the Balance parameter setting in this case study
is reported. This is due to the apparent diculty of the problem being signicantly
lowered. This is further discussed in Sections 8.3 and 8.5.
8.3 Experimental Results
Figures 8.1 and 8.2 contain single example convergence curves for two families of
experiments, namely, AK-Balance with one-point crossover and AK-Balance SDB
crossover respectively. Data for these gures consist of the best individual's raw
objective values at each generation that have then been normalized.
These gures illustrate that the convergence properties of this problem correspond
to those of the previous two case studies. Namely, Figure 8.1 demonstrates a tness
curve typically associated with EC studies and Figure 8.2 shows a method that is
converging quickly either due to selection pressure or lack of diversity in the popu-
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Figure 8.2: Alzheimer's AK-Balance with SDB crossover experiment tness curve
Setting LOO Sensitivity Avg. Best FE Avg. Median FE
Three-Balance 9/9 1.00 1181.42 30.24
Base-Balance 9/9 1.00 1272.37 24.97
AK-Balance 9/9 1.00 1828.56 901.28
sBet-Balance 9/9 1.00 1814.30 1170.43
sStress-Balance 9/9 1.00 1784.29 706.91
Table 8.2: Alzheimer's with one-point crossover experiment summary
lation. As discussed previously, it is certainly the case that SDB crossover possesses
extremely high exploitative properties in its current form.
Tables 8.2 and 8.3 contain experimental summary statistics computed as previ-
ously dened in Section 6.4.
Simply by inspection, it is clear that this problem is signicantly easier for this
methodology than the previous two case studies. Even in the case of the previously
under performing SDB crossover, all nine known genes are recovered with particularly
high FE values across all objective settings. Table 8.4 contains the individual LOO
successes rates on a gene by gene basis for the sBet-Balance parameter setting with
SDB crossover. This objective setting is selected as it successfully recovered all nine
Setting LOO Sensitivity Avg. Best FE Avg. Median FE
Three-Balance 9/9 1.00 1791.36 650.30
Base-Balance 9/9 1.00 1909.37 1187.79
AK-Balance 9/9 1.00 1899.23 1303.82
sBet-Balance 9/9 1.00 1942.23 1509.97
sStress-Balance 9/9 1.00 1838.50 1205.16
Table 8.3: Alzheimer's with SDB crossover experiment summary
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Gene Best Rank Median Rank Mean Rank Std Rank LOOs
HFE 1 10.00 11.07 8.63 30
NOS3 1 1.00 3.97 6.34 30
PLAU 1 10.50 10.57 7.98 30
A2M 1 1.00 1.50 3.42 30
MPO 1 47.00 42.80 23.75 30
APP 1 1.00 3.80 6.05 30
PSEN1 1 23.00 22.47 12.37 30
PSEN2 1 4.00 5.93 6.71 30
APOE 1 1.00 4.20 6.75 30
Table 8.4: sBet-Balance parameter setting with SDB crossover individual gene statis-
tics on Alzheimer's
Gene Description
CTNNB1 Catenin Beta 1
BGN Biglycan
CD59 CD59 Molecule (CD59 Blood Group)
CDH5 Cadherin 5
Table 8.5: Predicted genes for future Alzheimer's study.
known genes and produced the highest FE values. Remaining results are contained
in Section A.3.
As expected, Table 8.4 contains extremely stable and highly ranked results for
each known gene. The only two genes that the methodology did not have in the top
ten of its ranking were the genes MPO and PSEN1. However, all thirty test cases were
recovered easily. Further discussion on this set of known genes and future direction
for this case study is outlined in Section 8.5.
8.4 Predicted Genes
Table 8.5 contains potential new genes for study based on the top 1% most frequently
found non-xed genes that Genotator has conrmed to be linked to Alzheimer's dis-
ease.
The top gene for future study reported by this methodology is that of CTNNB1.
This gene is known to be responsible for protein creation that regulates connections
between cells. Typical health concerns associated with this gene are tumors and
various dierent types of cancers [52]. Despite this, multiple studies have shown
interaction between CTNNB1 and Alzheimer's [49][20].
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The BGN gene, which is known to be responsible for bone growth and muscle
development, does not necessarily have any explicit links to Alzheimer's in recent
studies. As such, this gene is a perfect candidate for future investigation in genetic
studies of Alzheimer's.
Upon further investigation, both the CD59 and CDH5 genes appear to already
be known as inuential genes with respect to Alzheimer's [75][51]. Going forward,
the known genes list should probably be expanded to include this pair as the data
generation for this case study was quite conservative.
8.5 Case Study Discussion and Conclusions
Unlike the previous case studies, the known genes for Alzheimer's were chosen in an
extremely conservative manner. As stated previously, this was done in part because
tools like Genotator did not natively possesses database entries for this disease. Ad-
ditionally this was done to provide a base point for comparison when using future
EC techniques, as Alzheimer's has been rarely studied in this manner. Due to this,
the diculty of the case study is signicantly reduced in comparison to the previ-
ous case studies, especially Parkinson's as seen by the performance of the previously
underwhelming SDB crossover.
A further complication with this case study is the lack of available comparative
databases (e.g. ENDEAVOUR) as tools using similar known gene setups. As outlined
in Section 8.4, future comparisons to this case study should potentially include both
the CD59 and CDH5 genes as they are already known Alzheimer's contributors.
Future methods could also seek to be less conservative when selecting the known
LOO genes, as this case study illustrates that the problem has sucient structure for
EC to exploit.
A second important conclusion previously outlined was the success of SDB crossover.
Now that the problem diculty has reduced, the highly exploitative nature of the
technique is signicantly more desirable. This implies that a modication to the
exchange process of SDB to include more explorative properties could drastically
improve the applicability to the previous case studies.
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Chapter 9
Conclusion
In sum, this work presented a multi-objective genetic algorithm which attempts to
evolve candidate communities of the most highly inuential genes related to a par-
ticular disease's presentation. This is achieved through aggregating several dierent
types of biological evidence relating genes together. Through these numerous re-
lations, complex networks are formed. These networks are then investigated via
centrality measures, with their values passed to the genetic algorithm as potential
tness objectives. As part of this work, three case studies were explored, namely,
breast cancer, Parkinson's, and as part of a new contribution, Alzheimer's. In each
case study, the most successful results were the shortest path based measures, stress
and betweenness, matching previous literature. Contrary to the original hypothesis,
the single-objective parameter settings for this study showed signicant success. This
conrms the notions that despite the widespread use of multi-objective approaches
in evolutionary computation, single-objective techniques still have their strengths.
However, the weakness of the Sum of Ranks could be due to the lack of diversity in
populations due to ties in ranks. Future use should include the notion of a diversity
penalty to combat this.
Furthermore, signicantly increased performance in both fold enrichment and sen-
sitivity metrics were shown in the case of breast cancer and Parkinson's relative to
past methodologies. Much of this success can be attributed to the inclusion of multiple
evidence types in the data generation stage of the Disease Gene Association Prob-
lem. This is echoed by the rise of weighted protein-protein interaction networks and
various graph rening techniques used in recent studies. In the case of Alzheimer's,
the success of this work implies that the problem has sucient structure for this
technique and others of a similar nature to exploit in the future.
Additional future work should include the renement of the safe dealer-based
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(SDB) crossover technique. Originally on breast cancer and Parkinson's, the tech-
nique was shown to be extremely exploitative. When presented with the easier prob-
lem of Alzheimer's, due to the conservative known gene selection it was able to pro-
duce the best results while remaining very stable. By introducing more variation into
the exchange portion of the operator, thus including more explorative properties, safe
dealer-based crossover could be a worthwhile crossover approach. As balancing explo-
ration and exploitation is part of every evolutionary computation technique, it is also
potentially worth trying dierent mutation techniques, selection techniques, as well
as tness methodologies in the future. This could also include the notion of switching
techniques during the search procedure, for example, switching to more explorative
techniques if the population begins to converge during execution. Another important
consideration would be to vary the elitism parameter to more carefully study selection
pressure in both crossover techniques. In order to compare these numerous potential
settings in the future, more rigorous statistical techniques such as ANOVA testing
should be used.
Another potential expansion would be the adaptation of the technique to use
weighted networks. This would also include exploration of various new path based
centrality measures in the hopes of detecting the troublesome genes in breast cancer
and Parkinson's as well as less understood diseases in the future. As this changes the
overall structure of the input networks, it would be potentially benecial to further
study the properties of the graphs generated by the generation process of this work.
In addition, despite the overall success of this methodology it should be noted
that this technique does not automatically generalize to all diseases, much like one
evolutionary computation technique does not generalize to all problems. However, the
approach has been crafted such that in the future, application of the methodology
only requires changes to the known disease genes, and as such the data generation
procedure.
Lastly, each predicted gene from all three case studies as part of the Disease Gene
Association Problem present potentially interesting future studies for biologists to
investigate as part of further understanding deadly diseases.
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Appendix A
Additional Experimental Analysis
This appendix contains subsets of the fully parsed output les for each disease studied.
A.1 Breast Cancer Summary
--------------------------------------------------
Disease: bc
Cross: base
3Balance:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,14,25.000000,29.466667,14.868929,29
BRCA2,20,54.500000,59.500000,35.032743,20
TP53,14,32.500000,47.766667,59.236337,29
AR,26,161.000000,232.800000,158.895411,8
ATM,20,259.000000,257.533333,171.863164,7
CHEK2,21,169.500000,230.200000,159.152150,11
STK11,69,407.000000,354.300000,109.370976,1
RAD51,104,415.000000,371.833333,108.263435,0
PTEN,111,414.000000,379.000000,94.920657,0
BARD1,15,60.000000,81.666667,74.682470,27
RB1CC1,26,135.500000,207.366667,154.770238,7
NCOA3,0,62.500000,76.700000,80.062971,22
PIK3CA,14,32.000000,80.066667,121.556836,25
PPM1D,186,420.500000,403.500000,60.768498,0
CASP8,14,145.500000,196.733333,145.721021,12
3HighCross:
71
Gene,Best,Median,Mean,Std,LOOs
BRCA1,0,41.000000,39.600000,21.740793,29
BRCA2,0,50.500000,68.166667,65.561281,25
TP53,0,58.000000,87.633333,94.863417,25
AR,39,346.000000,262.500000,120.512912,4
ATM,22,344.000000,245.400000,137.262547,7
CHEK2,23,346.500000,259.000000,133.357957,8
STK11,56,349.500000,297.066667,102.054730,1
RAD51,19,349.500000,298.066667,106.660251,4
PTEN,95,350.500000,312.133333,82.860803,0
BARD1,14,108.500000,110.866667,71.192664,21
RB1CC1,24,342.000000,249.400000,129.055615,10
NCOA3,14,70.500000,121.900000,121.057225,22
PIK3CA,0,42.000000,82.066667,96.104086,27
PPM1D,100,352.500000,322.333333,75.946593,0
CASP8,14,346.500000,284.166667,115.006472,7
3HighMut:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,14,22.500000,23.533333,8.696941,25
BRCA2,19,45.500000,46.700000,19.285782,21
TP53,14,21.000000,23.566667,9.291017,29
AR,42,182.000000,257.600000,184.403905,8
ATM,23,78.500000,141.933333,165.553603,13
CHEK2,52,130.000000,227.900000,198.276601,5
STK11,171,539.000000,462.233333,160.694116,0
RAD51,67,551.000000,397.400000,231.337133,1
PTEN,91,464.500000,421.733333,185.345332,0
BARD1,14,34.000000,51.000000,44.773761,28
RB1CC1,34,112.500000,198.433333,179.935177,5
NCOA3,17,45.000000,57.533333,43.905646,18
PIK3CA,15,23.000000,29.466667,17.363722,28
PPM1D,172,592.000000,536.100000,130.898315,0
CASP8,18,103.500000,164.066667,170.115160,11
Balance:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,14,24.500000,28.233333,11.813736,30
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BRCA2,18,49.500000,57.433333,32.735811,26
TP53,14,36.000000,66.566667,78.306948,26
AR,21,132.500000,174.333333,133.687317,13
ATM,25,364.500000,269.566667,170.089973,9
CHEK2,37,176.500000,247.733333,150.565585,4
STK11,134,404.000000,355.233333,103.650169,2
RAD51,27,405.000000,326.666667,138.560166,2
PTEN,86,411.000000,349.066667,113.968820,0
BARD1,14,62.500000,76.033333,50.214357,24
RB1CC1,14,158.000000,209.900000,161.435233,10
NCOA3,14,54.500000,114.466667,135.672713,19
PIK3CA,14,64.500000,89.500000,97.997449,27
PPM1D,149,408.000000,384.166667,74.183874,0
CASP8,14,69.000000,159.266667,159.803097,16
HighCross:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,0,43.500000,48.233333,33.282162,30
BRCA2,0,64.500000,71.433333,61.017060,23
TP53,0,55.500000,96.066667,100.280618,25
AR,33,299.000000,233.266667,124.512825,9
ATM,15,338.000000,280.433333,114.107839,5
CHEK2,23,330.500000,246.866667,129.747429,8
STK11,64,346.500000,323.966667,64.155782,0
RAD51,14,337.000000,270.033333,130.831158,4
PTEN,91,339.000000,303.033333,79.447004,0
BARD1,14,108.000000,115.600000,76.410236,25
RB1CC1,33,228.500000,205.333333,133.712335,13
NCOA3,14,59.500000,121.666667,117.498154,20
PIK3CA,14,38.000000,95.166667,121.181563,24
PPM1D,324,346.000000,345.300000,10.157891,0
CASP8,17,157.500000,188.400000,129.413691,15
HighMut:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,14,19.500000,20.766667,6.775632,27
BRCA2,21,41.000000,43.666667,20.608558,22
TP53,0,23.500000,28.266667,24.621176,29
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AR,30,153.000000,212.666667,178.917113,8
ATM,31,144.500000,312.300000,287.445725,8
CHEK2,22,162.000000,257.300000,237.055377,8
STK11,142,374.500000,462.166667,238.470281,0
RAD51,85,521.000000,486.800000,244.316556,3
PTEN,107,629.000000,521.633333,247.380969,0
BARD1,14,26.500000,44.566667,79.005318,26
RB1CC1,21,152.500000,203.666667,164.892093,5
NCOA3,15,41.000000,46.533333,29.534005,18
PIK3CA,14,23.000000,36.966667,23.417476,22
PPM1D,202,722.000000,668.500000,148.443360,0
CASP8,24,86.500000,159.500000,191.826745,12
akBalance:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,14,19.500000,20.733333,6.648481,30
BRCA2,23,76.500000,83.266667,37.438624,16
TP53,0,23.000000,29.400000,18.485036,30
AR,27,88.500000,176.266667,146.139030,9
ATM,15,72.000000,111.833333,119.400827,25
CHEK2,31,74.500000,104.700000,94.805118,22
STK11,68,213.500000,254.833333,139.501349,1
RAD51,14,56.500000,76.733333,97.566576,27
PTEN,30,188.000000,221.466667,134.907052,11
BARD1,15,39.500000,52.733333,62.252508,29
RB1CC1,14,60.500000,96.366667,100.572322,20
NCOA3,15,34.000000,42.600000,24.368719,29
PIK3CA,0,22.500000,23.266667,7.506013,30
PPM1D,59,258.500000,266.866667,142.389881,2
CASP8,15,83.500000,130.000000,130.033417,21
akHighCross:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,14,25.000000,26.366667,8.640256,30
BRCA2,20,63.000000,77.633333,70.184723,23
TP53,14,28.000000,34.566667,18.421658,30
AR,14,142.500000,184.633333,135.882678,13
ATM,0,60.500000,120.233333,129.783290,23
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CHEK2,24,125.500000,176.566667,131.334709,18
STK11,20,297.500000,244.200000,128.035394,5
RAD51,0,104.500000,148.433333,133.659806,20
PTEN,16,157.500000,202.633333,139.099687,10
BARD1,14,44.000000,58.866667,38.564530,30
RB1CC1,15,106.000000,177.200000,143.561449,15
NCOA3,0,48.500000,60.666667,40.893751,30
PIK3CA,0,37.500000,41.200000,26.058819,30
PPM1D,31,316.000000,257.000000,123.508202,5
CASP8,15,104.500000,166.666667,139.446772,17
akHighMut:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,0,18.500000,19.100000,6.707433,30
BRCA2,24,65.500000,77.000000,39.709288,14
TP53,14,20.000000,19.066667,3.938609,30
AR,42,102.500000,164.233333,148.983147,12
ATM,15,57.500000,89.800000,112.044757,25
CHEK2,15,81.000000,158.333333,180.053313,16
STK11,80,488.000000,383.266667,173.238710,2
RAD51,14,65.500000,125.000000,149.490168,19
PTEN,38,173.500000,255.966667,184.831607,7
BARD1,14,24.000000,25.300000,7.391281,30
RB1CC1,17,62.500000,127.866667,150.496359,17
NCOA3,14,24.500000,31.066667,16.986675,30
PIK3CA,14,21.000000,21.333333,4.943357,30
PPM1D,22,233.500000,296.400000,177.252324,2
CASP8,16,69.500000,111.800000,106.620629,18
sBetBalance:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,0,25.000000,25.533333,9.919446,30
BRCA2,15,65.500000,71.066667,36.910828,15
TP53,0,20.500000,19.166667,5.540343,30
AR,0,85.500000,100.466667,87.101896,13
ATM,0,40.500000,46.233333,26.390546,30
CHEK2,20,83.000000,103.166667,86.084995,21
STK11,33,220.000000,255.233333,150.548579,7
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RAD51,14,50.000000,83.966667,104.830399,26
PTEN,32,112.500000,174.466667,142.908153,12
BARD1,0,35.000000,36.300000,15.326673,30
RB1CC1,0,76.500000,115.000000,128.786645,19
NCOA3,0,31.000000,32.933333,15.591628,30
PIK3CA,14,21.000000,22.533333,8.617277,30
PPM1D,22,214.500000,245.866667,151.366131,3
CASP8,0,56.000000,102.166667,107.859450,21
sStressBalance:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,0,22.000000,22.400000,10.918507,30
BRCA2,21,62.000000,82.033333,53.871164,15
TP53,0,24.500000,31.133333,18.490880,30
AR,14,115.000000,178.366667,155.159869,11
ATM,20,67.500000,112.300000,121.290233,20
CHEK2,15,78.500000,139.100000,137.359420,16
STK11,134,424.500000,374.466667,101.607335,0
RAD51,31,119.000000,186.433333,154.259451,15
PTEN,29,182.500000,239.300000,154.011005,5
BARD1,0,28.500000,33.866667,18.687509,30
RB1CC1,20,95.000000,140.300000,128.704995,19
NCOA3,14,36.500000,41.900000,23.632751,27
PIK3CA,15,23.000000,27.500000,13.454265,30
PPM1D,112,416.000000,360.566667,114.200273,2
CASP8,27,120.500000,142.666667,99.117253,17
--------------------------------------------------
Cross: newcross
3Balance:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,0,25.000000,24.333333,11.414852,30
BRCA2,19,47.500000,55.533333,27.883666,24
TP53,0,25.500000,25.100000,10.639387,30
AR,108,333.000000,305.733333,123.695380,0
ATM,16,100.500000,160.400000,142.559752,13
CHEK2,108,307.000000,302.433333,116.809802,0
STK11,124,373.000000,364.500000,113.274385,0
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RAD51,112,369.000000,319.466667,135.075645,0
PTEN,155,378.000000,369.600000,80.357220,0
BARD1,0,24.500000,25.033333,13.435628,30
RB1CC1,102,220.000000,237.900000,117.013218,0
NCOA3,0,57.000000,58.866667,28.051349,28
PIK3CA,14,30.000000,31.300000,10.249138,30
PPM1D,150,430.000000,417.966667,108.392481,0
CASP8,16,81.500000,70.700000,27.545761,30
3HighCross:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,14,26.500000,29.700000,9.048338,30
BRCA2,20,71.500000,69.233333,28.876292,22
TP53,0,26.000000,25.066667,8.208210,30
AR,105,241.500000,240.766667,91.570468,0
ATM,16,145.500000,163.533333,98.620391,7
CHEK2,105,277.000000,262.866667,109.238977,0
STK11,138,338.500000,351.700000,84.738197,0
RAD51,110,331.500000,336.433333,109.624338,0
PTEN,119,355.000000,346.300000,115.014887,0
BARD1,0,30.000000,28.533333,12.610158,30
RB1CC1,121,298.500000,312.266667,107.598530,0
NCOA3,0,47.000000,55.466667,30.411810,27
PIK3CA,14,33.000000,36.000000,14.202962,30
PPM1D,131,328.000000,324.833333,98.476702,0
CASP8,14,77.500000,68.766667,23.992360,30
3HighMut:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,14,25.500000,26.733333,8.216608,30
BRCA2,30,92.500000,83.100000,26.437108,17
TP53,0,23.500000,22.766667,9.375990,30
AR,107,227.000000,266.966667,141.829544,0
ATM,23,101.000000,150.233333,123.763034,14
CHEK2,107,366.000000,331.533333,143.624687,0
STK11,144,424.500000,393.233333,107.481733,0
RAD51,127,443.500000,431.033333,128.765888,0
PTEN,138,424.000000,417.900000,105.514944,0
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BARD1,0,27.000000,28.033333,11.903298,30
RB1CC1,102,225.000000,235.966667,105.044320,0
NCOA3,0,63.500000,63.300000,30.828950,25
PIK3CA,0,25.500000,27.466667,9.978367,30
PPM1D,180,425.500000,444.500000,111.613480,0
CASP8,0,82.000000,70.233333,26.958056,30
Balance:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,0,23.000000,22.433333,10.849069,30
BRCA2,32,105.500000,104.300000,23.319594,5
TP53,0,23.500000,24.700000,9.074975,30
AR,104,249.000000,247.566667,114.211746,0
ATM,18,94.000000,125.566667,93.506291,21
CHEK2,106,322.000000,289.366667,129.424851,0
STK11,143,385.500000,398.433333,78.691315,0
RAD51,110,349.500000,342.733333,149.559568,0
PTEN,112,392.500000,383.000000,113.822911,0
BARD1,0,29.500000,29.633333,11.189537,30
RB1CC1,103,271.500000,275.233333,131.367787,0
NCOA3,0,59.500000,54.133333,26.497538,30
PIK3CA,0,25.000000,25.666667,8.687420,30
PPM1D,289,421.500000,422.766667,68.408854,0
CASP8,14,72.500000,64.600000,23.758265,30
HighCross:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,0,23.000000,24.800000,12.177990,30
BRCA2,25,101.500000,97.833333,28.399955,8
TP53,0,27.000000,26.900000,8.591696,30
AR,101,171.500000,193.900000,81.945461,0
ATM,0,99.500000,149.266667,116.842934,15
CHEK2,111,327.500000,305.966667,112.708193,0
STK11,140,372.000000,360.300000,92.758177,0
RAD51,108,350.000000,348.966667,109.391572,0
PTEN,242,370.500000,375.166667,78.665632,0
BARD1,0,25.500000,25.566667,12.883251,30
RB1CC1,101,245.500000,232.300000,83.920385,0
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NCOA3,14,58.000000,56.700000,26.634370,30
PIK3CA,0,27.000000,31.833333,18.678927,30
PPM1D,147,356.500000,360.833333,84.476107,0
CASP8,0,78.000000,69.133333,22.905704,30
HighMut:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,14,24.000000,24.766667,6.724548,30
BRCA2,68,102.000000,102.066667,9.291944,4
TP53,0,23.000000,23.033333,11.211089,30
AR,105,234.000000,244.400000,135.118747,0
ATM,0,96.500000,141.566667,96.555749,21
CHEK2,105,349.000000,339.133333,145.335221,0
STK11,140,410.000000,386.200000,123.276924,0
RAD51,116,452.000000,430.733333,127.908624,0
PTEN,136,456.500000,445.500000,121.505712,0
BARD1,0,31.000000,29.866667,13.927728,30
RB1CC1,103,161.000000,215.233333,128.225739,0
NCOA3,17,58.000000,55.466667,20.885126,30
PIK3CA,15,24.500000,28.366667,9.426607,30
PPM1D,207,476.500000,459.833333,126.156193,0
CASP8,14,64.000000,59.500000,25.825342,30
akBalance:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,0,22.500000,19.500000,8.873634,30
BRCA2,101,130.000000,157.066667,57.033525,0
TP53,0,23.500000,19.566667,10.798095,30
AR,94,108.000000,146.700000,58.827715,1
ATM,0,40.500000,41.300000,19.044684,30
CHEK2,15,72.000000,65.100000,23.765159,30
STK11,109,323.000000,301.233333,109.439854,0
RAD51,0,63.500000,55.366667,22.748222,30
PTEN,101,275.000000,259.833333,115.673763,0
BARD1,0,24.000000,21.700000,13.365292,30
RB1CC1,16,66.000000,61.466667,22.992852,30
NCOA3,0,34.000000,33.600000,18.587352,30
PIK3CA,16,25.000000,25.000000,4.168850,30
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PPM1D,108,339.000000,320.566667,93.999884,0
CASP8,0,76.000000,67.066667,24.244350,30
akHighCross:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,0,24.000000,21.233333,8.377652,30
BRCA2,102,159.500000,173.933333,62.259708,0
TP53,0,23.500000,19.733333,10.660702,30
AR,100,129.000000,157.366667,63.283970,0
ATM,0,48.000000,42.933333,15.813424,30
CHEK2,0,72.500000,68.000000,20.384240,30
STK11,109,305.500000,292.533333,83.216682,0
RAD51,0,50.000000,47.266667,24.343707,30
PTEN,107,235.500000,246.766667,83.223291,0
BARD1,0,27.000000,26.366667,9.488590,30
RB1CC1,0,73.500000,65.333333,24.196513,30
NCOA3,0,38.500000,35.200000,12.026981,30
PIK3CA,0,25.000000,23.266667,7.714444,30
PPM1D,121,301.500000,296.833333,83.974989,0
CASP8,0,73.000000,67.000000,22.685253,30
akHighMut:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,0,21.500000,17.466667,9.754692,30
BRCA2,101,117.000000,153.600000,63.858464,0
TP53,0,22.000000,18.633333,10.499535,30
AR,100,148.000000,154.600000,53.344424,0
ATM,17,43.500000,44.066667,14.975689,30
CHEK2,20,79.000000,70.433333,21.607284,30
STK11,119,414.000000,390.900000,128.583624,0
RAD51,30,63.500000,60.633333,15.075633,30
PTEN,102,224.000000,236.033333,108.394071,0
BARD1,0,22.000000,19.066667,10.859394,30
RB1CC1,0,60.500000,56.533333,25.856012,30
NCOA3,0,33.500000,31.933333,13.670843,30
PIK3CA,0,24.500000,21.066667,11.094992,30
PPM1D,118,394.000000,358.233333,153.715071,0
CASP8,14,75.500000,63.933333,24.133156,30
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sBetBalance:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,0,20.000000,18.633333,9.880260,30
BRCA2,104,162.000000,170.200000,56.012560,0
TP53,0,19.000000,15.366667,9.129276,30
AR,22,86.500000,71.066667,27.268693,30
ATM,0,33.000000,34.033333,13.777752,30
CHEK2,0,61.500000,59.266667,22.726156,30
STK11,116,294.500000,303.600000,134.645793,0
RAD51,0,45.500000,42.933333,22.666903,30
PTEN,100,203.000000,186.900000,70.993127,0
BARD1,0,23.500000,19.933333,10.546885,30
RB1CC1,0,63.000000,55.733333,25.550401,30
NCOA3,0,28.000000,27.466667,13.778377,30
PIK3CA,0,22.000000,16.233333,10.496907,30
PPM1D,102,275.500000,271.100000,96.725830,0
CASP8,0,60.000000,52.966667,18.342495,30
sStressBalance:
Gene,Best,Median,Mean,Std,LOOs
BRCA1,0,20.500000,18.133333,8.161023,30
BRCA2,102,183.500000,191.266667,70.753059,0
TP53,0,23.500000,21.533333,9.860172,30
AR,100,211.500000,221.866667,121.528125,0
ATM,0,65.000000,60.400000,19.340149,30
CHEK2,17,75.500000,68.166667,25.106783,30
STK11,115,350.000000,330.933333,107.377174,0
RAD51,0,69.500000,57.900000,24.050737,30
PTEN,119,276.000000,312.700000,131.214788,0
BARD1,0,24.000000,21.800000,11.943545,30
RB1CC1,0,76.500000,67.466667,25.146102,30
NCOA3,0,44.500000,46.100000,17.323196,30
PIK3CA,0,25.000000,22.966667,9.901178,30
PPM1D,107,375.500000,365.200000,108.029179,0
CASP8,100,140.000000,160.600000,64.380121,0
--------------------------------------------------
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A.2 Parkinson's Summary
--------------------------------------------------
Disease: park
Cross: base
3Balance:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,279,423.000000,420.066667,30.640218,0
GAK,337,422.500000,421.600000,20.978807,0
MAOB,17,92.000000,91.266667,46.249647,7
PON1,20,83.000000,176.500000,161.366097,17
COMT,323,426.000000,418.700000,27.050591,0
GBA,396,426.000000,426.700000,12.961880,0
BST1,14,51.000000,144.633333,159.825440,22
DRD2,37,57.000000,61.033333,15.744694,17
LRRK2,335,425.500000,424.900000,21.367636,0
MAPT,19,176.000000,223.133333,155.235690,12
PINK1,14,410.000000,301.400000,177.334401,9
APOE,86,413.000000,338.800000,123.060792,0
BDNF,210,424.000000,403.233333,60.984273,0
PARK2,0,14.000000,14.033333,2.760351,30
SNCA,0,14.000000,13.833333,2.666307,30
3HighCross:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,128,366.000000,348.833333,56.991278,0
GAK,171,360.000000,350.500000,49.257067,0
MAOB,22,64.000000,74.366667,44.401369,10
PON1,30,253.000000,214.266667,139.055914,15
COMT,199,361.500000,352.533333,39.935926,0
GBA,222,360.000000,351.300000,32.531311,0
BST1,21,180.500000,193.533333,154.168232,15
DRD2,51,80.000000,83.433333,19.155774,3
LRRK2,130,364.000000,352.266667,51.827255,0
MAPT,22,79.500000,152.133333,134.766396,16
PINK1,28,361.000000,345.966667,64.871482,1
APOE,68,350.500000,263.266667,128.058697,1
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BDNF,172,361.500000,345.733333,56.987557,0
PARK2,0,14.000000,13.133333,4.516127,30
SNCA,0,14.000000,14.000000,2.779233,30
3HighMut:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,242,579.000000,537.966667,112.053092,0
GAK,237,578.000000,563.600000,65.410428,0
MAOB,18,32.000000,32.266667,9.013145,20
PON1,25,138.000000,220.766667,194.509406,15
COMT,272,560.500000,535.033333,80.462235,0
GBA,491,590.000000,587.933333,26.155943,0
BST1,17,44.500000,104.933333,149.225803,22
DRD2,18,28.500000,30.266667,6.872902,23
LRRK2,199,580.000000,564.866667,82.677910,0
MAPT,37,112.500000,204.066667,198.919310,13
PINK1,15,142.500000,290.066667,259.168023,11
APOE,121,339.500000,383.700000,190.874060,0
BDNF,213,552.000000,512.100000,100.967509,0
PARK2,0,14.000000,13.300000,3.640292,30
SNCA,0,14.000000,13.266667,3.628749,30
Balance:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,173,418.000000,402.200000,55.853503,0
GAK,251,415.500000,412.900000,33.023868,0
MAOB,37,91.500000,116.300000,93.701341,5
PON1,16,66.500000,117.233333,117.043665,24
COMT,181,422.500000,409.000000,57.258639,0
GBA,259,412.500000,406.566667,37.927047,0
BST1,14,381.500000,275.400000,171.380923,12
DRD2,50,76.500000,80.500000,18.810764,13
LRRK2,296,419.000000,415.600000,29.460201,0
MAPT,14,204.500000,227.266667,156.084401,8
PINK1,14,415.500000,365.100000,130.770225,4
APOE,106,419.000000,358.866667,116.280201,0
BDNF,385,421.500000,420.000000,15.058507,0
PARK2,0,14.000000,14.566667,3.588135,30
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SNCA,0,14.000000,13.333333,3.660915,30
HighCross:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,228,359.000000,350.433333,30.853026,0
GAK,196,358.000000,346.166667,40.744861,0
MAOB,28,59.000000,69.766667,38.090349,13
PON1,14,104.000000,157.600000,124.528518,20
COMT,168,355.000000,347.700000,36.905424,0
GBA,187,353.000000,348.833333,33.223468,0
BST1,15,338.000000,263.333333,130.891725,7
DRD2,53,87.500000,83.533333,17.260146,6
LRRK2,335,356.000000,356.166667,10.923191,0
MAPT,14,341.500000,286.466667,110.710786,6
PINK1,14,352.000000,313.100000,103.282121,3
APOE,84,218.500000,236.066667,114.633128,0
BDNF,168,358.000000,350.000000,36.931437,0
PARK2,0,14.000000,13.500000,3.730120,30
SNCA,0,14.000000,13.900000,4.221047,30
HighMut:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,209,515.000000,465.466667,134.758208,0
GAK,349,575.500000,559.366667,58.975438,0
MAOB,24,39.500000,45.100000,18.846659,22
PON1,25,100.500000,181.600000,186.039039,16
COMT,316,568.000000,563.100000,57.514226,0
GBA,425,586.500000,572.700000,45.681166,0
BST1,14,154.000000,268.666667,235.045019,16
DRD2,24,32.000000,36.300000,11.884937,24
LRRK2,286,579.500000,553.533333,73.620056,0
MAPT,53,169.000000,248.866667,212.472916,8
PINK1,14,569.000000,472.966667,221.078935,5
APOE,110,547.000000,473.466667,153.916174,0
BDNF,201,567.000000,535.700000,96.213179,0
PARK2,14,14.000000,14.533333,0.776079,30
SNCA,14,14.000000,14.400000,0.770132,30
akBalance:
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Gene,Best,Median,Mean,Std,LOOs
CYP2D6,140,430.000000,400.366667,91.638527,0
GAK,91,417.500000,324.666667,140.850699,1
MAOB,15,21.000000,31.300000,16.966803,26
PON1,21,75.500000,178.700000,180.400732,18
COMT,56,411.500000,313.333333,145.772930,3
GBA,333,433.000000,427.866667,22.504763,0
BST1,15,34.500000,52.333333,72.639086,30
DRD2,0,18.500000,17.700000,4.251977,30
LRRK2,124,431.500000,406.100000,74.783066,0
MAPT,15,100.500000,179.266667,158.570975,11
PINK1,16,41.000000,52.666667,34.855696,30
APOE,22,153.500000,211.566667,159.780169,6
BDNF,32,83.500000,132.933333,120.905188,9
PARK2,0,15.000000,13.300000,5.324958,30
SNCA,0,15.000000,11.866667,6.724804,30
akHighCross:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,197,370.000000,355.333333,43.502147,1
GAK,15,357.500000,268.200000,134.670581,5
MAOB,15,22.500000,30.833333,31.751278,26
PON1,15,123.000000,160.800000,130.724084,22
COMT,28,358.500000,264.433333,141.041369,8
GBA,287,370.500000,368.866667,18.451677,0
BST1,15,48.000000,84.100000,100.204739,27
DRD2,15,19.000000,18.500000,3.170445,30
LRRK2,67,364.000000,347.933333,58.564985,0
MAPT,15,303.000000,218.833333,157.937588,14
PINK1,15,52.500000,105.866667,107.570581,26
APOE,22,119.500000,197.400000,148.487919,9
BDNF,22,98.500000,149.633333,130.190440,16
PARK2,0,15.000000,11.200000,6.880257,30
SNCA,0,15.000000,12.566667,6.468402,30
akHighMut:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,138,504.500000,447.500000,132.574702,0
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GAK,52,303.000000,325.900000,181.600234,2
MAOB,15,20.000000,20.700000,5.246674,28
PON1,26,74.500000,133.566667,146.240870,20
COMT,83,330.500000,324.233333,162.054415,3
GBA,368,520.500000,513.266667,42.973876,0
BST1,0,28.000000,34.566667,24.909053,30
DRD2,0,16.000000,16.566667,3.910052,30
LRRK2,95,521.500000,499.033333,83.672796,0
MAPT,44,149.500000,253.900000,203.537398,12
PINK1,15,40.500000,56.333333,87.366976,29
APOE,55,280.000000,318.500000,199.481181,2
BDNF,27,93.000000,146.366667,151.621462,14
PARK2,0,15.000000,14.333333,3.933353,30
SNCA,0,15.000000,9.633333,7.462473,30
sBetBalance:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,231,429.000000,412.133333,56.231500,0
GAK,47,383.000000,286.200000,159.804708,1
MAOB,0,23.500000,45.200000,58.191953,26
PON1,16,74.000000,173.766667,173.851638,18
COMT,19,351.500000,278.000000,167.333036,5
GBA,313,434.000000,426.400000,32.031881,0
BST1,15,29.500000,44.766667,35.093651,30
DRD2,15,18.000000,17.833333,2.018592,30
LRRK2,99,434.000000,411.000000,80.990847,0
MAPT,15,140.000000,201.833333,161.363390,12
PINK1,0,43.000000,65.000000,78.154136,29
APOE,34,160.500000,224.433333,159.681079,9
BDNF,20,74.000000,135.566667,144.351268,18
PARK2,0,15.000000,13.400000,5.385805,30
SNCA,0,15.000000,12.266667,6.263927,30
sStressBalance:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,83,425.500000,377.133333,103.394702,1
GAK,81,410.500000,324.433333,136.419152,2
MAOB,15,21.500000,37.866667,30.772506,21
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PON1,26,94.000000,165.066667,150.369873,16
COMT,36,421.500000,331.300000,138.533489,3
GBA,336,430.000000,429.066667,23.561999,0
BST1,0,31.500000,53.666667,81.841450,29
DRD2,0,18.500000,17.633333,4.156286,30
LRRK2,348,427.500000,428.500000,21.413418,0
MAPT,25,265.500000,246.000000,177.650762,10
PINK1,0,39.500000,65.866667,101.674509,28
APOE,18,206.000000,253.366667,167.848964,5
BDNF,33,152.500000,187.933333,129.630492,5
PARK2,0,15.000000,13.733333,4.675197,30
SNCA,0,15.000000,13.166667,6.063363,30
--------------------------------------------------
Cross: newcross
3Balance:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,289,452.500000,460.766667,93.716993,0
GAK,343,499.500000,500.466667,88.368637,0
MAOB,115,139.500000,147.000000,30.326954,0
PON1,16,62.500000,56.766667,21.495281,30
COMT,159,483.000000,475.000000,101.654248,0
GBA,319,504.000000,504.133333,88.618412,0
BST1,16,28.000000,30.633333,9.034353,30
DRD2,124,132.000000,133.200000,6.784363,0
LRRK2,210,493.500000,504.366667,122.899870,0
MAPT,21,92.000000,98.600000,35.321772,22
PINK1,15,34.500000,101.666667,141.412659,23
APOE,179,525.500000,518.400000,112.357066,0
BDNF,229,467.000000,484.266667,91.701891,0
PARK2,14,15.000000,15.666667,1.787569,30
SNCA,0,15.000000,14.900000,4.451656,30
3HighCross:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,147,431.000000,406.166667,97.059556,0
GAK,324,454.500000,464.166667,85.591284,0
MAOB,115,145.000000,192.133333,96.172522,0
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PON1,15,65.000000,56.900000,19.511889,30
COMT,196,414.000000,432.100000,88.611648,0
GBA,179,404.500000,398.966667,110.538957,0
BST1,0,28.500000,28.166667,10.888410,30
DRD2,121,134.500000,135.833333,10.079283,0
LRRK2,140,443.500000,461.533333,115.707936,0
MAPT,25,92.500000,105.200000,61.701394,19
PINK1,0,234.000000,214.233333,187.877378,14
APOE,219,471.500000,464.466667,94.292185,0
BDNF,154,413.500000,421.433333,91.242641,0
PARK2,0,16.000000,16.333333,5.228129,30
SNCA,0,15.000000,14.533333,4.629242,30
3HighMut:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,185,483.000000,484.866667,113.347721,0
GAK,390,514.500000,535.833333,99.751444,0
MAOB,117,137.000000,140.666667,21.598744,0
PON1,21,55.000000,56.466667,21.074144,30
COMT,324,504.000000,518.866667,103.818055,0
GBA,315,527.500000,523.066667,97.576472,0
BST1,18,27.000000,29.566667,9.320661,30
DRD2,120,130.000000,130.500000,5.876605,0
LRRK2,267,487.500000,497.333333,104.745779,0
MAPT,28,81.000000,79.000000,38.964175,28
PINK1,17,40.000000,106.700000,120.172907,23
APOE,151,470.000000,477.100000,100.218847,0
BDNF,398,540.500000,551.400000,92.926593,0
PARK2,0,15.000000,14.666667,5.516954,30
SNCA,14,15.000000,16.266667,2.066704,30
Balance:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,199,436.500000,440.400000,88.427878,0
GAK,353,444.000000,451.200000,62.541242,0
MAOB,120,153.000000,198.233333,101.358253,0
PON1,16,62.500000,55.300000,19.738200,30
COMT,231,456.000000,453.100000,90.477412,0
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GBA,309,452.000000,471.133333,83.154088,0
BST1,0,32.000000,32.133333,11.361561,30
DRD2,125,140.000000,143.700000,11.377988,0
LRRK2,346,441.000000,455.666667,81.505800,0
MAPT,100,205.500000,210.000000,89.342811,0
PINK1,34,100.000000,211.233333,178.355454,17
APOE,184,436.500000,439.966667,88.011160,0
BDNF,185,457.500000,451.666667,94.300815,0
PARK2,0,15.000000,15.666667,3.726266,30
SNCA,0,15.000000,15.633333,5.034251,30
HighCross:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,320,369.000000,392.133333,57.895109,0
GAK,332,413.000000,409.400000,62.117575,0
MAOB,126,203.000000,245.233333,126.924817,0
PON1,15,49.000000,51.300000,19.248197,30
COMT,258,361.500000,389.266667,62.708374,0
GBA,165,403.000000,402.666667,91.185046,0
BST1,19,33.500000,35.266667,12.250076,30
DRD2,127,150.500000,149.300000,10.609527,0
LRRK2,327,400.000000,400.000000,55.702411,0
MAPT,98,130.000000,159.466667,60.783808,2
PINK1,15,302.500000,257.400000,177.907880,10
APOE,319,428.500000,433.933333,56.257985,0
BDNF,201,418.000000,419.966667,82.898976,0
PARK2,0,15.000000,15.533333,4.695804,30
SNCA,14,17.000000,17.500000,2.956582,30
HighMut:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,316,479.500000,482.800000,85.758040,0
GAK,392,491.000000,502.633333,67.030864,0
MAOB,125,142.000000,152.200000,35.282505,0
PON1,15,60.500000,57.200000,20.988338,30
COMT,213,497.000000,502.666667,118.241813,0
GBA,399,483.000000,504.100000,68.840821,0
BST1,16,30.000000,33.400000,12.472314,30
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DRD2,125,138.000000,136.666667,8.635665,0
LRRK2,407,516.000000,520.500000,79.233287,0
MAPT,100,187.500000,210.066667,102.796060,0
PINK1,25,45.500000,55.666667,26.290595,30
APOE,174,520.500000,518.800000,112.764142,0
BDNF,214,492.500000,497.866667,92.243581,0
PARK2,0,15.000000,16.000000,4.008611,30
SNCA,0,15.000000,15.266667,5.698961,30
akBalance:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,120,424.500000,414.000000,102.098668,0
GAK,105,299.000000,317.700000,131.972346,0
MAOB,15,32.000000,31.033333,6.435266,30
PON1,0,67.000000,54.466667,22.955329,30
COMT,225,357.500000,368.000000,91.435298,0
GBA,259,390.000000,417.833333,83.749661,0
BST1,0,24.000000,23.300000,5.421223,30
DRD2,22,100.000000,76.633333,34.979288,9
LRRK2,194,419.500000,426.433333,85.215622,0
MAPT,22,98.000000,96.800000,31.678776,27
PINK1,0,23.000000,22.266667,5.105327,30
APOE,103,323.500000,300.733333,148.574823,0
BDNF,103,238.500000,222.800000,87.886055,0
PARK2,0,17.000000,14.500000,7.744854,30
SNCA,0,15.000000,11.600000,7.976690,30
akHighCross:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,229,390.000000,382.166667,85.200406,0
GAK,119,304.000000,302.266667,108.833290,0
MAOB,0,40.500000,43.200000,16.857210,30
PON1,30,67.000000,61.800000,13.246730,30
COMT,218,321.000000,339.033333,79.145646,0
GBA,280,361.000000,364.533333,65.016037,0
BST1,0,23.000000,21.866667,6.431246,30
DRD2,17,100.000000,70.600000,37.531228,11
LRRK2,107,384.500000,381.500000,90.958782,0
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MAPT,20,94.500000,84.000000,21.706506,28
PINK1,0,23.500000,20.233333,9.313258,30
APOE,101,272.500000,285.266667,128.082122,0
BDNF,108,239.500000,240.933333,93.046126,0
PARK2,0,15.000000,13.633333,7.402159,30
SNCA,0,15.000000,12.433333,8.045917,30
akHighMut:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,152,443.500000,433.966667,121.539970,0
GAK,112,396.000000,372.500000,116.547090,0
MAOB,0,30.000000,28.266667,7.597338,30
PON1,17,65.000000,59.300000,17.356605,30
COMT,109,412.000000,409.700000,116.634753,0
GBA,192,445.000000,435.833333,92.027014,0
BST1,0,22.500000,21.633333,5.397850,30
DRD2,27,100.000000,97.733333,13.364733,1
LRRK2,103,455.000000,431.066667,108.051052,0
MAPT,42,99.000000,95.033333,13.137163,26
PINK1,0,22.000000,19.300000,8.816716,30
APOE,102,253.000000,258.966667,103.608175,0
BDNF,102,261.500000,272.566667,141.118850,0
PARK2,0,16.000000,15.766667,6.026856,30
SNCA,0,16.000000,14.500000,6.981503,30
sBetBalance:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,259,395.500000,412.933333,78.693615,0
GAK,143,332.500000,354.733333,120.965636,0
MAOB,0,32.000000,31.166667,8.952300,30
PON1,0,60.500000,56.133333,19.236699,30
COMT,101,307.500000,293.466667,121.676715,0
GBA,325,404.000000,412.800000,70.948451,0
BST1,0,23.000000,19.233333,9.186509,30
DRD2,100,100.000000,100.500000,0.629724,0
LRRK2,108,440.000000,440.100000,104.554012,0
MAPT,100,138.000000,168.700000,76.395590,0
PINK1,0,22.500000,20.566667,6.719418,30
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APOE,100,225.000000,215.400000,102.976261,0
BDNF,100,115.000000,137.500000,43.697826,0
PARK2,0,16.000000,14.700000,7.139738,30
SNCA,0,16.000000,14.866667,6.306720,30
sStressBalance:
Gene,Best,Median,Mean,Std,LOOs
CYP2D6,256,422.500000,413.133333,79.341572,0
GAK,201,358.000000,373.766667,102.303026,0
MAOB,20,33.000000,32.766667,5.418254,30
PON1,0,58.500000,56.666667,22.921656,30
COMT,109,352.000000,351.433333,114.137148,0
GBA,185,421.500000,421.366667,86.908387,0
BST1,0,24.000000,22.366667,5.281610,30
DRD2,0,22.000000,23.366667,15.182756,29
LRRK2,240,398.000000,400.333333,71.439549,0
MAPT,17,85.000000,73.133333,26.385384,30
PINK1,0,24.000000,23.666667,7.023769,30
APOE,105,340.500000,315.566667,119.705582,0
BDNF,111,243.500000,253.800000,111.605957,0
PARK2,0,16.000000,15.100000,5.554433,30
SNCA,0,16.000000,14.166667,7.719583,30
--------------------------------------------------
A.3 Alzheimer's Summary
--------------------------------------------------
Disease: alz
Cross: base
3Balance:
Gene,Best,Median,Mean,Std,LOOs
HFE,8,46.000000,77.666667,92.793182,26
NOS3,18,426.000000,313.200000,168.654595,7
PLAU,0,32.000000,64.933333,95.246299,28
A2M,8,48.500000,91.800000,100.335781,25
MPO,8,96.000000,173.533333,164.734422,11
APP,8,335.000000,263.866667,191.641500,11
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PSEN1,8,112.500000,218.400000,200.534561,11
PSEN2,0,84.500000,169.433333,173.646824,20
APOE,0,36.000000,80.366667,111.122326,26
Balance:
Gene,Best,Median,Mean,Std,LOOs
HFE,9,97.500000,118.200000,91.697554,22
NOS3,0,362.000000,313.300000,169.104977,7
PLAU,8,33.500000,81.266667,116.292418,27
A2M,0,45.000000,138.900000,164.188989,22
MPO,8,129.000000,203.333333,171.480839,15
APP,0,357.500000,270.100000,181.387060,11
PSEN1,8,96.500000,194.733333,177.319881,19
PSEN2,0,51.000000,145.900000,166.821678,21
APOE,0,63.000000,98.933333,101.599258,27
akBalance:
Gene,Best,Median,Mean,Std,LOOs
HFE,0,24.500000,34.066667,46.284676,30
NOS3,0,9.000000,9.000000,3.107277,30
PLAU,0,19.000000,19.233333,15.021096,30
A2M,0,0.000000,2.400000,4.064989,30
MPO,13,72.000000,91.800000,84.220319,27
APP,0,12.000000,14.633333,9.041984,30
PSEN1,0,47.000000,66.600000,72.374314,29
PSEN2,0,11.000000,10.166667,5.669540,30
APOE,0,0.000000,4.000000,4.785034,30
sBetBalance:
Gene,Best,Median,Mean,Std,LOOs
HFE,9,22.000000,33.366667,25.932915,30
NOS3,0,0.000000,3.166667,4.259540,30
PLAU,0,17.500000,20.600000,12.310915,30
A2M,0,0.000000,1.166667,3.040909,30
MPO,15,50.500000,82.466667,102.583770,23
APP,0,8.500000,7.566667,4.240066,30
PSEN1,9,42.000000,42.600000,34.139269,30
PSEN2,0,8.000000,6.733333,4.877346,30
APOE,0,0.000000,2.166667,4.161261,30
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sStressBalance:
Gene,Best,Median,Mean,Std,LOOs
HFE,9,21.000000,25.966667,14.782290,30
NOS3,0,11.000000,10.800000,3.872093,30
PLAU,8,15.500000,16.800000,7.694154,30
A2M,0,0.000000,3.300000,4.442351,30
MPO,19,53.500000,69.433333,48.239119,28
APP,9,16.500000,22.033333,12.092983,30
PSEN1,8,44.500000,84.066667,96.279741,27
PSEN2,0,13.000000,12.333333,5.591455,30
APOE,0,8.000000,6.133333,4.658943,30
--------------------------------------------------
Cross: newcross
3Balance:
Gene,Best,Median,Mean,Std,LOOs
HFE,0,20.500000,20.433333,11.437034,30
NOS3,0,18.500000,16.466667,9.420203,30
PLAU,0,21.000000,20.100000,9.848333,30
A2M,0,11.000000,10.633333,6.562607,30
MPO,17,100.500000,144.333333,90.128771,14
APP,0,18.000000,18.100000,7.734161,30
PSEN1,0,54.000000,56.566667,42.541406,29
PSEN2,0,10.000000,9.066667,8.270985,30
APOE,0,10.000000,11.500000,6.647530,30
Balance:
Gene,Best,Median,Mean,Std,LOOs
HFE,0,17.500000,16.200000,7.617584,30
NOS3,0,9.000000,10.400000,5.021334,30
PLAU,0,16.000000,15.233333,5.405510,30
A2M,0,0.000000,5.033333,6.435266,30
MPO,0,57.500000,52.300000,24.265983,30
APP,0,8.000000,9.366667,8.164192,30
PSEN1,0,34.000000,33.000000,10.888146,30
PSEN2,0,10.000000,10.166667,6.086069,30
APOE,0,9.000000,9.200000,7.485158,30
akBalance:
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Gene,Best,Median,Mean,Std,LOOs
HFE,0,18.500000,15.133333,8.381973,30
NOS3,0,0.000000,5.466667,7.426575,30
PLAU,0,10.500000,9.666667,8.326664,30
A2M,0,0.000000,3.533333,5.981197,30
MPO,0,44.500000,44.100000,19.046857,30
APP,0,8.000000,8.566667,8.037341,30
PSEN1,0,33.500000,29.433333,14.928989,30
PSEN2,0,0.000000,6.133333,7.775884,30
APOE,0,0.000000,3.433333,6.162642,30
sBetBalance:
Gene,Best,Median,Mean,Std,LOOs
HFE,0,10.000000,11.066667,8.630073,30
NOS3,0,0.000000,3.966667,6.338080,30
PLAU,0,10.500000,10.566667,7.981372,30
A2M,0,0.000000,1.500000,3.421534,30
MPO,0,47.000000,42.800000,23.752169,30
APP,0,0.000000,3.800000,6.053782,30
PSEN1,0,23.000000,22.466667,12.372755,30
PSEN2,0,4.000000,5.933333,6.705290,30
APOE,0,0.000000,4.200000,6.748691,30
sStressBalance:
Gene,Best,Median,Mean,Std,LOOs
HFE,0,14.500000,11.466667,9.587108,30
NOS3,0,9.000000,9.566667,7.959741,30
PLAU,0,15.000000,12.866667,8.427105,30
A2M,0,0.000000,3.166667,5.711956,30
MPO,0,62.500000,53.766667,21.884782,30
APP,0,9.000000,9.066667,7.570056,30
PSEN1,0,40.500000,38.700000,15.778969,30
PSEN2,0,9.000000,9.800000,8.675769,30
APOE,0,0.000000,5.300000,6.555598,30
--------------------------------------------------
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